WO2022087475A1 - Reverse transcription of polynucleotides comprising unnatural nucleotides - Google Patents

Reverse transcription of polynucleotides comprising unnatural nucleotides Download PDF

Info

Publication number
WO2022087475A1
WO2022087475A1 PCT/US2021/056334 US2021056334W WO2022087475A1 WO 2022087475 A1 WO2022087475 A1 WO 2022087475A1 US 2021056334 W US2021056334 W US 2021056334W WO 2022087475 A1 WO2022087475 A1 WO 2022087475A1
Authority
WO
WIPO (PCT)
Prior art keywords
unnatural
nucleotide
rna
cdna
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/056334
Other languages
English (en)
French (fr)
Inventor
Floyd E. Romesberg
Xiyu DONG
Anne Xiaozhou ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Synthorx Inc
Original Assignee
Scripps Research Institute
Synthorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2023004690A priority Critical patent/MX2023004690A/es
Priority to CA3196205A priority patent/CA3196205A1/en
Priority to AU2021364920A priority patent/AU2021364920A1/en
Priority to JP2023524597A priority patent/JP2023547615A/ja
Priority to KR1020237016545A priority patent/KR20230088898A/ko
Priority to IL302243A priority patent/IL302243A/en
Application filed by Scripps Research Institute, Synthorx Inc filed Critical Scripps Research Institute
Priority to CN202180079118.6A priority patent/CN116761885A/zh
Priority to EP21884025.4A priority patent/EP4232570A4/en
Publication of WO2022087475A1 publication Critical patent/WO2022087475A1/en
Priority to US18/304,993 priority patent/US20230392140A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/10—Nucleotidyl transfering
    • C12Q2521/107—RNA dependent DNA polymerase,(i.e. reverse transcriptase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/101—Modifications characterised by incorporating non-naturally occurring nucleotides, e.g. inosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/155—Modifications characterised by incorporating/generating a new priming site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/179—Modifications characterised by incorporating arbitrary or random nucleotide sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/185—Modifications characterised by incorporating bases where the precise position of the bases in the nucleic acid string is important
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/131—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/179—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Definitions

  • RNA oligonucleotides can function as aptamers that recognize a specific target, e.g., for purposes of inhibiting or detecting the target.
  • the screening and selection of RNA aptamers from oligonucleotide libraries generally involves a reverse transcription step to convert the RNA into cDNA. Accordingly, to develop RNA aptamers comprising unnatural nucleotides, there is also a need for methods of reverse transcribing RNA comprising unnatural nucleotides.
  • Embodiment 1 is a method of reverse transcribing a polynucleotide comprising an unnatural ribonucleotide, comprising reverse transcribing the polynucleotide with a reverse transcriptase in the presence of an unnatural dNTP comprising an unnatural nucleobase, wherein the reverse transcriptase polymerizes a cDNA into which the unnatural dNTP is incorporated as an unnatural nucleotide.
  • Embodiment 2 is the method of embodiment 1, wherein: the polynucleotide is present at a concentration less than or equal to about 500 nM.
  • Embodiment 2. 1 is the method of any one of the preceding embodiments, wherein the reverse transcriptase is SuperScript III.
  • Embodiment 2.2 is the method of any one of the preceding embodiments, wherein the unnatural dNTP is not dTPT3TP.
  • Embodiment 2.3 is the method of any one of the preceding embodiments, wherein the method further comprises measuring the amount of the unnatural nucleotide in the cDNA using a binding partner that recognizes the unnatural nucleotide.
  • Embodiment 2.4 is the method of any one of the preceding embodiments, wherein the reverse transcriptase produces full length cDNA and at least 25% of the full length cDNA comprises the unnatural nucleotide.
  • Embodiment 2.5 is the method of any one of the preceding embodiments, wherein the polynucleotide is a tRNA, mRNA, RNA aptamer, or a member of a plurality of RNA aptamer candidates.
  • Embodiment 3 is the method of any one of the preceding embodiments, wherein the polynucleotide is an RNA, optionally wherein the RNA is an mRNA or tRNA.
  • Embodiment 4 is the method of any one of embodiments 1 -3, further comprising measuring the amount of the unnatural nucleotide in the cDNA.
  • Embodiment 5 is a method of measuring incorporation of an unnatural nucleotide, comprising: a. transcribing a polynucleotide comprising an unnatural deoxyribonucleotide with an RNA polymerase in the presence of an unnatural NTP comprising a first unnatural nucleobase to produce an RNA comprising a first unnatural nucleotide; b . reverse transcribing the RNA with a reverse transcriptase in the presence of an unnatural dNTP comprising a second unnatural nucleobase, wherein the reverse transcriptase polymerizes a cDNA into which the unnatural NTP is incorporated as a second unnatural nucleotide; and c. measuring the amount of the second unnatural nucleotide in the cDNA.
  • Embodiment 5. 1 is the method of embodiment 5, which is a method of measuring combined fidelity of transcription and reverse transcription.
  • Embodiment 5.2 is the method of embodiment 5, which is a method of measuring retention of an unnatural nucleotide during transcription and reverse transcription.
  • Embodiment 6 is the method of any one of embodiments 5-5.2, wherein the transcribing step is in vivo.
  • Embodiment 7 is the method of the immediately preceding embodiment, wherein the transcribing step is in a prokaryote or bacterium.
  • Embodiment 8 is the method of the immediately preceding embodiment, wherein the transcribing step is in E. coli.
  • Embodiment 9 is the method of embodiment 5, wherein the transcribing step is in vitro.
  • Embodiment 10 is the method of any one of embodiments 5 -9, wherein the amount of the second unnatural nucleotide in the cDNA molecule is measured relative to the amount of the unnatural deoxyribonucleotide in the polynucleotide before transcription.
  • Embodiment 11 is the method of any one of embodiments 5-10, wherein the measuring comprises: a. performing a biotin shift assay on the polynucleotide before transcription to determine the proportion of the polynucleotide before transcription that contains the unnatural nucleotide; and b. performing a biotin shift assay on the cDNA to determine the proportion of the cDNA that contains containing the unnatural nucleotide.
  • Embodiment 12 is the method of any one of embodiments 4-10, wherein the amount of the unnatural nucleotide or the second unnatural nucleotide in the cDNA is measured using a binding partner that binds an unnatural nucleobase.
  • Embodiment 13 is the method of any one of embodiments 4-10, wherein measuring the amount of the unnatural nucleotide or the second unnatural nucleotide in the cDNA comprises a gel shift assay or biotin shift assay.
  • Embodiment 14 is the method of the immediately preceding embodiment, wherein the biotin shift assay comprises: a. amplifying the cDNA in the presence of an unnatural dNTP comprising a biotinylated nucleobase that pairs with the unnatural nucleotide in the cDNA; b . separating DNA amplification products comprising the biotinylated nucleotide from DNA amplification products not comprising the biotinylated nucleotide; and c.
  • Embodiment 15 is the method of the immediately preceding embodiment, wherein separating DNA amplification products comprising the biotinylated nucleotide from DNA amplification products not comprising the biotinylated nucleobase comprises gel electrophoresis, optionally wherein the gel electrophoreses is polyacrylamide gel electrophoresis.
  • Embodiment 16 is the method of any one of embodiments 14-15, wherein separating DNA amplification products comprising the biotinylated nucleotide fromDNA amplification products not comprising the biotinylated nucleotide comprises incubating the amplification products with streptavidin.
  • Embodiment 17 is the method of any one of the preceding embodiments, wherein the RNA or polynucleotide is present during reverse transcription at a concentration less than or equal to about 1 ⁇ M.
  • Embodiment 18 is the method of any one of the preceding embodiments, wherein the RNA or polynucleotide is present during reverse transcription at a concentration in the range of about 1-10 nM, about 10-20 nM, about20-30 nM, about30-40 nM, about40-50 nM, about 50- 75 nM, about75-100 nM, about 100-150 nM, about 150-200 nM, about 200-300 nM, about300- 400 nM, or about 400-500 nM.
  • Embodiment 19 is the method of any one of the preceding embodiments, wherein the reverse transcriptase produces full length cDNA and wherein at least 25% of the full length cDNA comprises the unnatural nucleotide.
  • Embodiment 20 is the method of the immediately preceding embodiment, wherein at least 50%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% of the non-truncatedcDNA comprises the unnatural nucleotide.
  • Embodiment 21 is the method of any one of the preceding embodiments, wherein the RNA or polynucleotide comprising the unnatural ribonucleotide is an mRNA.
  • Embodiment 22 is the method of embodiment 20, wherein the unnatural ribonucleotide (X or Y) is located at the first position (X-N-N or Y-N-N) of a codon of the mRNA.
  • Embodiment 23 is the method of embodiment 20, wherein the unnatural ribonucleotide (X or Y) is located at the middle position (N-X-N orN-Y-N) of a codon of the mRNA.
  • Embodiment 24 is the method of embodiment 20, wherein the unnatural ribonucleotide (X or Y) is located at the last position (N-N-X orN-N-Y) of a codon of the mRNA.
  • Embodiment 25 is the method of any one of embodiments 51-25, wherein the codon containing the unnatural ribonucleotide in the mRNA is AXC, AYC, GXC, GYC, GXT, GYT, AXA, AXT, TXA, or TXT.
  • Embodiment 26 is the method of any one of embodiments 1 -20, wherein the RNA or polynucleotide comprising the unnatural ribonucleotide is a tRNA.
  • Embodiment 27 is the method of embodiment 26, wherein the unnatural ribonucleotide (X or Y) is located at the first position (X-N-N or Y-N-N) of the anticodon of the tRNA.
  • Embodiment 28 is the method of embodiment 26, wherein the unnatural ribonucleotide
  • (X or Y) is located at the middle position (N-X-N orN-Y-N) of the anticodon ofthe tRNA.
  • Embodiment 29 is the method of embodiment 26, wherein the unnatural ribonucleotide
  • (X or Y) is located at the last position (N-N-X or N-N-Y) of the anticodon of the tRNA.
  • Embodiment 30 is the method of any one of embodiments 26-29, wherein the anticodon of the tRNA is GYT, GXT, GYC, GXC, CYA, CXA, AYC, or AXC.
  • Embodiment 31 is the method of any one of embodiments 1 -30, wherein the unnatural ribonucleotide is X, wherein X comprises s the nucleobase of the unnatural ribonucleotide (NaM).
  • Embodiment 32 is the method of any one of embodiments 1 -30, wherein the unnatural ribonucleotide is Y, wherein Y comprises as the nucleobase of the unnatural ribonucleotide (TPT3).
  • Embodiment 33 is the method of any one of embodiments 1 -20 or 31 -32, wherein the RNA is an RNA aptamer.
  • Embodiment 34 is a method of screening RNA aptamer candidates comprising: a. incubating a plurality of different RNA oligonucleotides with a target, wherein the RNA oligonucleotides comprise at least one unnatural nucleotide; b. performing at least one round of selection for RNA oligonucleotides of the plurality that bind to the target; c. isolating enriched RNA oligonucleotides that bind to the target, wherein the isolated enriched RNA oligonucleotides comprise RNA aptamers; and d.
  • RNA aptamers reverse transcribing one or more of the RNA aptamers into cDNAs, wherein the cDNAs comprise an unnatural deoxyribonucleotide at the position complementary to the at least one unnatural nucleotide in the RNA aptamer, thereby providing a library of cDNA molecules corresponding to the RNA aptamers.
  • Embodiment 35 is the method of the immediately preceding embodiment, wherein the plurality of different RNA oligonucleotides comprise a randomized nucleotide region.
  • Embodiment 36 is the method of the immediately preceding embodiment, wherein the randomized nucleotide region comprises the at least one unnatural nucleotide.
  • Embodiment 37 is the method of any one of embodiments 34-36, wherein the RNA oligonucleotides comprise barcode sequences and/or primer binding sequences.
  • Embodiment 38 is the method of any one of embodiments 34-37, wherein the method further comprises sequencing the cDNA molecules.
  • Embodiment 39 is the method of any one of embodiments 34-38, wherein performing at least one round of selection comprises a wash step to remove unbound or weakly bound RNA oligonucleotides.
  • Embodiment 40 is the method of any one of embodiments 34-39, wherein the method further comprises mutating the sequence of the cDNA molecules to generate a plurality of additional sequences.
  • Embodiment 41 is the method of the immediately preceding embodiment, wherein the plurality of additional sequences is transcribed into RNA and subjected to at least one additional round of selection for RNA aptamers that bind to the target.
  • Embodiment 42 is the method of any one of embodiments 40-41, wherein mutating the sequence of the cDNA molecules comprises error-prone PCR.
  • Embodiment 43 is the method of any one of embodiments 34-42, wherein the method further comprises increasing selection pressure for binding to the target in an additional round of selection.
  • Embodiment 44 is the method of the immediately preceding embodiment, wherein increasing selection pressure comprises performing one or more washing steps at a higher salt concentration than in a previous round and/or including a binding competitor during the selection.
  • Embodiment 45 is the method of any one of embodiments 34-44, further comprising analyzing the RNA aptamers for their ability to bind the target.
  • Embodiment 46 is the method of the immediately preceding embodiment, wherein analyzing the RNA aptamers for their ability to bind the target comprises determining a K k on , ork oS .
  • Embodiment 47 is the method of any one of embodiments 34-44, further comprising analyzing the RNA aptamers fortheir ability to agonize the target.
  • Embodiment 48 is the method of the immediately preceding embodiment, wherein analyzing the RNA aptamers for their ability to agonize the target comprises determining an EC50 value.
  • Embodiment 49 is the method of any one of embodiments 34-44, further comprising analyzing the RNA aptamers fortheir ability to antagonize the target.
  • Embodiment 50 is The method of the immediately preceding embodiment, wherein analyzing the RNA aptamers for their ability to antagonize the target comprises determining a Ki or IC 50 value.
  • Embodiment 51 is the method of any one of the preceding embodiments, wherein at least one unnatural nucleotide comprises:
  • Embodiment 52 is the method of the immediately preceding embodiment, wherein at least one unnatural nucleotide in a polynucleotide that undergoes reverse transcription comprises:
  • Embodiment 53 is the method of embodiment 51 or 52, wherein at least one unnatural nucleotide that is incorporated into cDNA comprises: , and optionally wherein the at least one unnatural nucleobase in the unnatural nucleotide is different from the at least one unnatural nucleobase in the polynucleotide that undergoes reverse transcription.
  • Embodiment 54 is the method of any one of embodiments 51-53, wherein the atleast one unnatural nucleotidee comprises: [0070]
  • Embodiment 55 is the method of embodiments 51-53, wherein the at least one unnatural nucleotide comprises
  • Embodiment 56 is the method of any one of the preceding embodiments, wherein the reverse transcriptase is Avian Myeloblastosis Virus (AMV) reverse transcriptase, Moloney Murine Leukemia Virus (MMLV) reverse transcriptase, Super Script II (SS II) reverse transcriptase, Super Script III (SS III) reverse transcriptase, Super Script IV (SS IV) reverse transcriptase, or Volcano 2G (V2G) reverse transcriptase.
  • AMV Avian Myeloblastosis Virus
  • MMLV Moloney Murine Leukemia Virus
  • SS II Super Script II
  • SS III Super Script III
  • SS IV Super Script IV reverse transcriptase
  • V2G Volcano 2G
  • Embodiment 57 is the method of any one of the preceding embodiments, wherein the reverse transcriptase is SuperScript III.
  • Embodiment 58 is the method of any one of the preceding embodiments, wherein the unnatural dNTP is not dTPT3TP.
  • Embodiment 59 is the method of any one of the preceding embodiments, wherein the reverse transcribing takes place in vitro.
  • FIG. 1 shows unnatural base pairs between dNAM and dTPT3, and betweenNaM and TPT3.
  • FIG. 2 shows a denaturing gel for cDNA detection and qualitative biotin shift of cDNA in different reverse transcription (RT) reaction conditions.
  • FIG. 3 shows full-length cDNA ratio as a function of RNA concentration in RT reactions using SuperScript III.
  • FIG. 4 shows a schematic of an exemplary transcription-reverse transcription (T-RT) process for measuring unnatural nucleotide retention.
  • FIGS. 5A-B show fidelity levels in T-RT retention assays for sequences comprising the indicated codons.
  • FIG. 6 shows images of denaturing gels for cDNA detection with different codons and anticodons.
  • FIGS. 7A-B show T-RT retention of mRNA from in vivo translation experiments for sequences comprising the indicated codons (with previously reported protein shift values shown below where available).
  • FIGS. 8A-B show dependency of mRNA transcription fidelity onNaMTP concentration of TPT3TP concentration, respectively, in an in vivo translation experiment.
  • ranges and amounts can be expressed as “about” a particular value or range. About also includes the exact amount. Hence “about 5 ⁇ L” means “about 5 ⁇ L” and also “5 ⁇ L.” Generally, the term “about” includes an amount that would be expected to be within experimental error.
  • an “analog” of a chemical structure refers to a chemical structure that preserves substantial similarity with the parent structure, although it may not be readily derived synthetically from the parent structure.
  • a nucleotide analog is an unnatural nucleotide.
  • a nucleoside analog is an unnatural nucleoside.
  • a related chemical structure that is readily derived synthetically from a parent chemical structure is referred to as a “derivative.”
  • Nucleotides are comprised of a nucleobase, a sugar, and at least one phosphate. Nucleotide can thus refer to nucleoside triphosphates, the substrates of RNA and DNA polymerases, nucleoside diphosphates, or nucleoside monophosphates, of which DNA and RNA are comprised. Nucleotides encompasses naturally occurring nucleotides or unnatural nucleotides (i.e., nucleotide analogs). Naturally occurring nucleotides include nucleotides found in naturally occurring DNA or RNA, including naturally occurring deoxyribonucleotides and ribonucleotides.
  • Unnatural nucleotides contain some type of difference from the nucleobase, sugar, and/or phosphate moieties in naturally occurring nucleotides.
  • a modified nucleotide comprises modification of one or more of the 3 ’OH or 5’OH group, the backbone, the sugar component, or the nucleobase, and/or addition of non-naturally occurring linker molecules.
  • Unnatural nucleotides include DNA or RNA analogs (e.g., containing nucleobase analogs, sugar analogs and/or a non -native backbone and the like).
  • a “nucleoside” is a compound comprising a nucleobase moiety and a sugar moiety.
  • Nucleosides include, but are not limited to, naturally occurring nucleosides (corresponding to the nucleotides found in DNA and RNA), modified nucleosides, and nucleosides having mimetic nucleobases and/or sugar groups.
  • Nucleosides include nucleosides comprising any variety of substituents.
  • a nucleoside can be a glycoside compound formed through glycosidic linking between a nucleobase and a reducing group of a sugar.
  • a “nucleobase” is generally the heterocyclic portion of a nucleoside, and maybe aromatic or partially unsaturated.
  • the nucleobase does not include the sugar component of the nucleoside or nucleotide (e.g., ribose, deoxyribose, or analog thereof; examples of sugar analogs, also referred to as modified sugars, are described elsewhere herein) .
  • Nucleobases may be naturally occurring, may be modified, may bear no similarity to natural nucleobases, and may be synthesized, e.g., by organic synthesis.
  • a nucleobase comprises any atom or group of atoms capable of interacting with a nucleobase of another nucleic acid with or without the use of hydrogen bonds.
  • an unnatural nucleobase is not derived from a natural nucleobase. It should be noted that unnatural nucleobases do not necessarily possessbasic properties; however, they are referred to as nucleobases for simplicity.
  • a“(d)” indicates that the nucleobase can be attached to a deoxyribose or a ribose. Nucleobases are also commonly referred to as bases.
  • the unnatural mRNA codons and unnatural tRNA anticodons as described in the present disclosure can be written in terms of their DNA coding sequence.
  • an unnatural tRNA anticodon can be written as GYU or GYT.
  • Polynucleotides can be synthesized in automated synthesizers, e.g., using phosph oroamidite chemistry or other chemical approaches adapted for synthesizer use.
  • DNA includes, but is not limited to, cDNA and genomic DNA. DNA may be attached, by covalent or non-covalent means, to another biomolecule, including, but not limited to, RNA or a peptide.
  • RNA includes coding RNA, e.g. messenger RNA (mRNA). In some embodiments, RNA is rRNA, RNAi, snoRNA, microRNA, siRNA, snRNA, exRNA, piRNA, long ncRNA, or any combination or hybrid thereof. In some instances, RNA is a component of a ribozyme. DNA and RNA can be in any form, including, but not limited to, linear, circular, supercoiled, single-stranded, and double-stranded.
  • mRNA is an RNA comprising an ORF capable of being translated by a ribosome.
  • a “tRNA” is an RNA capable of being charged with a natural amino acid or a ncAA and participatingin translation of an mRNA by a ribosome.
  • a peptide nucleic acid is a synthetic DNA/RNA analog wherein a peptide -like backbone replaces the sugar-phosphate backbone of DNA or RNA.
  • PNA oligomers show higher binding strength and greater specificity in binding to complementary DNAs, with a PNA/DNA base mismatch being more destabilizing than a similar mismatch in a DNA/DNA duplex. This binding strength and specificity also applies to PNA/RNA duplexes.
  • PNAs are not easily recognized by either nucleases or proteases, making them resistant to enzyme degradation. PNAs are also stable over a wide pH range. See also Nielsen PE, Egholm M, Berg RH, Buchardt O (December 1991).
  • a locked nucleic acid is a modified RNA nucleotide, wherein the ribose moiety of an LNA nucleotide is modified with an extra bridge connecting the 2' oxygen and 4' carbon.
  • the bridge "locks" the ribose in the 3'-endo (North) conformation, which is often found in the A-form duplexes.
  • LNA nucleotides can be mixed with DNA or RNA residues in the oligonucleotide whenever desired. Such oligomers can be synthesized chemically and are commercially available.
  • the locked ribose conformation enhances nucleobase stacking and backbone pre-organization.
  • an “aptamer” refers an oligonucleotide that can specifically bind a target, e.g., with high affinity. Aptamers may comprise RNA and may comprise natural or unnatural nucleotides. [0099] As used herein, “full length” means that a polynucleotide such as a cDNA is non- truncated relative to the complementary sequence thattemplated its synthesis (template polynucleotide).
  • the full length polynucleotide comprises a nucleotide in the position complementary to the unnatural nucleotide in the template polynucleotide and further nucleotides 3 ’ thereof.
  • a full length polynucleotide is in contrast to a truncated polynucleotide, which results from termination of synthesis before completion, e.g., at or near the position complementary to the unnatural nucleotide in the template polynucleotide.
  • the polynucleotide can be reverse transcribed with a reverse transcriptase in the presence of an unnatural dNTP comprising an unnatural nucleobase.
  • the reverse transcriptase polymerizes cDNA into which the unnatural NTP is incorporated, e.g., in a position of the cDNA complementary to the position of the unnatural ribonucleotide in the polynucleotide.
  • the polynucleotide is present at a concentration less than or equal to about 500 nM.
  • the RNA or polynucleotide is present during reverse transcription at a concentration in the range of about 1 -10 nM, about 10-20 nM, about 20-30 nM, about 30-40 nM, about 40-50 nM, about 50-75 nM, about 75-100 nM, about 100-150 nM, about 150-200 nM, about 200-300 nM, about 300-400 nM, or about 400-500 nM.
  • the concentration is at or below about lOO nM, e.g., about 5-100 nM, such as about 10-100 nM. In some embodiments, the concentration is at or below about 50 nM, e.g., about 5-50 nM, such as about 10-50 nM. In some embodiments, the concentration is at or below about 30 nM, e.g., about 5-30 nM, such as about 10-30 nM. As described in the examples, using a lower concentration than previous attempts to reverse transcribe polynucleotides comprising an unnatural nucleotide may improve performance of the reverse transcription reaction.
  • the reverse transcriptase is Avian Myeloblastosis Virus (AMV) reverse transcriptase, Moloney Murine Leukemia Virus (MMLV) reverse transcriptase, Super Script II (SS II) reverse transcriptase, Super Script III (SS III) reverse transcriptase, Super Script IV (SS IV) reverse transcriptase, or Volcano 2G (V2G) reverse transcriptase.
  • AMV Avian Myeloblastosis Virus
  • MMLV Moloney Murine Leukemia Virus
  • SS II Super Script II
  • SS III Super Script III
  • SS IV Super Script IV reverse transcriptase
  • V2G Volcano 2G
  • the reverse transcriptase is SuperScript III (e.g., available from ThermoFisher Scientific, Cat. No. 18080093).
  • SuperScript III is a genetically engineered MMLV reverse transcriptase that was created by introduction of several mutations for reduced RNase H activity, increased half
  • the polynucleotide comprising the unnatural ribonucleotide can be any suitable substrate for the reverse transcriptase, e.g., RNA, an RNA-DNA fusion, or DNA. Reverse transcriptases are known to accept DNA or RNA-DNA hybrids as substrates in addition to RNA.
  • the polynucleotide comprising the unnatural ribonucleotide is an RNA.
  • the RNA can be an mRNA.
  • the RNA can be a tRNA.
  • the RNA can be an RNA aptamer, or a member of a plurality of aptamer candidates (often referred to as a “library”), e.g., wherein the plurality of aptamer candidates undergoes reverse transcription in the same or different reaction vessels or chambers.
  • the polynucleotide(s) in any of the foregoing embodiments may comprise other modifications in addition to the unnatural nucleotide; for example, there can be an unnatural nucleotide comprising an unnatural nucleobase and, at the same and/or other nucleotide positions, modifications to the nucleobase or one or more sugars and/or phosphates.
  • the unnatural ribonucleotide may be located in a codon.
  • the unnatural nucleotide may occur in the first, second, or third position of the codon.
  • Exemplary codons are AXC, AYC, GXC, GYC, GXT, GYT, AXA, AXT, TXA, or TXT, where the unnatural ribonucleotide may be represented by X or Y.
  • X comprises the nucleobase of the unnatural ribonucleotide (NaM; here and throughout, for clarity only the nucleobase portion of the unnatural deoxy- or ribonucleotide/nucleoside is shown) and/or Y comprises as the nucleobase of the unnatural ribonucleotide (TPT3).
  • NaM unnatural ribonucleotide
  • TPT3 unnatural ribonucleotide
  • the unnatural ribonucleotide may be located in the anticodon of the tRNA.
  • the unnatural nucleotide may occur in the first, second, or third position of the anticodon.
  • Exemplary anticodons are GYT, GXT, GYC, GXC, CYA, CXA, AYC, or
  • AXC where the unnatural ribonucleotide maybe represented by X or Y.
  • X or Y may be represented by X or Y.
  • X comprises s the nucleobase of the unnatural ribonucleotide (NaM) and/or Y comprises the nucleobase of the unnatural ribonucleotide (TPT3).
  • unnatural nucleobases are known and can be used as the unnatural nucleobase in the dNTP and/or the unnatural ribonucleotide.
  • the unnatural nucleobase is independently selected from a group consisting some embodiments, the unnatural dNTP is not dTPT3TP.
  • the unnatural nucleobase is selected from those shown below, wherein the wavy line or R identifies a point of attachment to the sugar (e.g., deoxyribose or ribose):
  • the nucleobase comprises the structure: , wherein each X is independently carbon or nitrogen; R 2 is optional and when present is independently hydrogen, alkyl, alkenyl, alkynyl; methoxy, methanethiol, methaneseleno, halogen, cyano, or azide group; wherein each Y is independently sulfur, oxygen, selenium, or secondary amine; wherein each E is independently oxygen, sulfur or selenium; and wherein the wavy line indicates a point of bonding to a ribosyl, deoxyribosyl, or dideoxyribosyl moiety or an analog thereof, wherein the ribosyl, deoxyribosyl, or dideoxyribosyl moiety or analog thereof is in free form, connected to a mono-phosphate, diphosphate, or triphosphate group, optionally comprising an ⁇ -thiotriphosphate, ⁇ -thiotriphosphate, or ⁇ -thio
  • R 2 is lower alkyl (e.g., C 1 -C 6 ), hydrogen, or halogen. In some embodiments of a nucleobase described herein, R 2 is fluoro. In some embodiments of a nucleobase described herein, X is carbon. In some embodiments of a nucleobase described herein, E is sulfur. In some embodiments of a nucleobase described herein, Y is sulfur. In some embodiments of a nucleobase described herein, a nucleobase has the structure: . In some embodiments of a nucleobase described herein, E is sulfur and Y is sulfur.
  • the wavy line indicates a point of bonding to a ribosyl or deoxyribosyl moiety. In some embodiments of a nucleobase described herein, the wavy line indicates a point of bonding to a ribosyl or deoxyribosyl moiety, connected to a triphosphate group.
  • the nucleobase is a component of a nucleic acid polymer. In some embodiments, the nucleobase is a component of a tRNA. In some embodiments, the nucleobase is a component of an anticodon in a tRNA. In some embodiments, the nucleobase is a component of an mRNA. In some embodiments, the nucleobase is a component of a codon of an mRNA. In some embodiments, the nucleobase is a component of RNA or DNA. In some embodiments, the nucleobase is a component of a codon in DNA. In some embodiments, the nucleobase forms a nucleobase pair with another complementary nucleobase.
  • unnatural nucleobases include 2-thiouracil, 2’ -deoxyuridine, 4- thio-uracil, uracil-5-yl, hypoxanthin-9-yl (I), 5-halouracil; 5-propynyl-uracil, 6-azo-uracil, 5- methylaminomethyluracil, 5 -methoxyaminomethyl-2 -thiouracil, pseudouracil, uracil-5- oxacetic acid methylester, uracil-5-oxacetic acid, 5 -methyl -2 -thiouracil, 3-(3-amino-3-N-2- carboxypropyl) uracil, 5-methyl-2-thiouracil, 4-thiouracil, 5 -methyluracil, 5’- methoxycarboxymethyluracil, 5 -methoxyuracil, uracil-5 -oxyacetic acid, 5- (carb oxy hydroxylmethyl) urac
  • the unnatural nucleobase is selected from uracil-5-yl, hypoxanthin-9-yl (I), 2-aminoadenin-9-yl, 5 -methylcytosine (5-me-C), 5 -hydroxymethyl cytosine, xanthine, hypoxanthine, 2 -aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2 -thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5 -prop ynyl uracil and cytosine, 6- azo uracil, cytosine and thymine, 5 -uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl,
  • Certain unnatural nucleic acids such as 5-substituted pyrimidines, 6 -azapyrimidines and N-2 substituted purines, N-6 substituted purines, 0-6 substituted purines, 2 -aminopropyladenine, 5-propynyluracil, 5 -propynyl cytosine, 5- methylcytosine, those that increase the stability of duplex formation, universal nucleic acids, hydrophobic nucleobases, promiscuous nucleobases, size-expanded nucleobases, fluorinated nucleobases, 5 -substituted pyrimidines, 6 -azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2 -aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
  • nucleic acids comprising various heterocyclic nucleobases and various sugar moieties (and sugar analogs) are available in the art, and the nucleic acid in some cases include one or several heterocyclic nucleobases other than the principal five nucleobase components of naturally-occurring nucleic acids.
  • the heterocyclic nucleobase includes, in some cases, uracil-5-yl, cytosin-5-yl, adenin-7-yl, adenin-8-yl, guanin-7-yl, guanin-8-yl, 4- aminopyrrolo [2.3-d] pyrimidin-5-yl, 2-amino-4-oxopyrolo [2, 3-d] pyrimidin-5-yl, 2- amino-4- oxopyrrolo [2.3-d] pyrimidin-3-yl groups, where the purines are attached to the sugar moiety of the nucleic acid via the 9-position, the pyrimidines via the 1 -position, the pyrrolopyrimidines via the 7-position and the pyrazolopyrimidines via the 1-position.
  • nucleotide analogs are also modified at the phosphate moiety.
  • Modified phosphate moieties include, but are not limited to, those with modification at the linkage between two nucleotides and contains, for example, a phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, methyl and other alkyl phosphonates including 3’-alkylene phosphonate and chiral phosphonates, phosphinates, phosphoramidates including 3’-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates.
  • these phosphate or modified phosphate linkage between two nucleotides are through a 3’-5’ linkage or a 2’-5’ linkage, and the linkage contains inverted polarity such as 3’-5’ to 5’-3’ or 2’-5’ to 5’-2’.
  • Various salts, mixed salts and free acid forms are also included.
  • nucleotides containing modified phosphates include but are not limited to, 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.
  • unnatural nucleic acids include 2’,3’-dideoxy-2’,3’-didehydro- nucleosides (PCT/US2002/006460), 5’-substituted DNA and RNA derivatives (PCT/US2011/033961; Saha et al., J.
  • unnatural nucleic acids include modifications at the 5’-position and the 2’-position of the sugar ring (PCT/US94/02993), such as 5’-CH 2 -substituted 2’-O- protected nucleosides (Wu et al., Helvetica Chimica Acta, 2000, 83, 1127-1143 and Wu et al., Bioconjugate Chem.1999, 10, 921-924).
  • unnatural nucleic acids include amide linked nucleoside dimers have been prepared for incorporation into oligonucleotides wherein the 3’ linked nucleoside in the dimer (5’ to 3’) comprises a 2’-OCH 3 and a 5’-(S)-CH 3 (Mesmaeker et al., Synlett, 1997, 1287-1290).
  • Unnatural nucleic acids can include 2’-substituted 5’-CH 2 (or O) modified nucleosides (PCT/US92/01020).
  • Unnatural nucleic acids can include 5’- methylenephosphonate DNA and RNA monomers, and dimers (Bohringer et al., Tet.
  • Unnatural nucleic acids can include 5’-phosphonate monomers having a 2’-substitution (US2006/0074035) and other modified 5’-phosphonate monomers (WO1997/35869).
  • Unnatural nucleic acids can include 5’-modified methylenephosphonate monomers (EP614907 and EP629633).
  • Unnatural nucleic acids can include analogs of 5’ or 6’-phosphonate ribonucleosides comprising a hydroxyl group at the 5’ and/or 6’-position (Chen et al., Phosphorus, Sulfur and Silicon, 2002, 777, 1783-1786; Jung et al., Bioorg. Med. Chem., 2000, 8, 2501-2509; Gallier et al., Eur. J. Org. Chem., 2007, 925-933; and Hampton et al., J. Med. Chem., 1976, 19(8), 1029-1033).
  • Unnatural nucleic acids can include 5’-phosphonate deoxyribonucleoside monomers and dimers having a 5’-phosphate group (Nawrot et al., Oligonucleotides, 2006, 16(1), 68-82).
  • Unnatural nucleic acids can include nucleosides having a 6’-phosphonate group wherein the 5’ or/and 6’-position is unsubstituted or substituted with a thio-tert-butyl group (SC(CH 3 ) 3 ) (and analogs thereof); a methyleneamino group (CH 2 NH 2 ) (and analogs thereof) or a cyano group (CN) (and analogs thereof) (Fairhurst et al., Synlett, 2001, 4, 467-472; Kappler et al., J. Med. Chem., 1986, 29, 1030-1038; Kappler et al., J. Med.
  • unnatural nucleic acids also include modifications of the sugar moiety.
  • nucleic acids contain one or more nucleosides wherein the sugar group has been modified.
  • nucleic acids comprise a chemically modified ribofuranose ring moiety.
  • a modified nucleic acid comprises modified sugars or sugar analogs.
  • the sugar moiety can be pentose, deoxypentose, hexose, deoxyhexose, glucose, arabinose, xylose, lyxose, or a sugar “analog” cyclopentyl group.
  • the sugar can be in a pyranosyl or furanosyl form.
  • the sugar moiety may be the furanoside of ribose, deoxyribose, arabinose or 2’-O-alkylribose, and the sugar can be attached to the respective heterocyclic nucleobases either in [alpha] or [beta] anomeric configuration.
  • Sugar modifications include, but are not limited to, 2’-alkoxy-RNA analogs, 2’-amino-RNA analogs, 2’-fluoro-DNA, and 2’-alkoxy- or amino-RNA/DNA chimeras.
  • a sugar modification may include 2’-O-methyl-uridine or 2’-O-methyl-cytidine.
  • Sugar modifications include 2’-O-alkyl-substituted deoxyribonucleosides and 2’-O-ethyleneglycol like ribonucleosides.
  • the preparation of these sugars or sugar analogs and the respective “nucleosides” wherein such sugars or analogs are attached to a heterocyclic nucleobase (nucleic acid base) is known.
  • Sugar modifications may also be made and combined with other modifications. [00119] Modifications to the sugar moiety include natural modifications of the ribose and deoxy ribose as well as unnatural modifications.
  • Sugar modifications include, but are not limited to, the following modifications at the 2’ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C 1 to C 10 , alkyl or C 2 to C 10 alkenyl and alkynyl.2’ sugar modifications also include but are not limited to -O[(CH 2 ) n O] m CH 3 , -O(CH 2 ) n OCH 3 , -O(CH 2 ) n NH 2 , -O(CH 2 ) n CH 3 , -O(CH 2 ) n ONH 2 , and -O(CH 2 ) n ON[(CH 2 )n CH 3 )] 2 , where n and
  • Modified sugars also include those that contain modifications at the bridging ring oxygen, such as CH 2 and S.
  • Nucleotide sugar analogs may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
  • nucleic acids having modified sugar moieties include, without limitation, nucleic acids comprising 5’-vinyl, 5’-methyl (R or S), 4’-S, 2’-F, 2’-OCH 3 , and 2’- O(CH 2 ) 2 OCH 3 substituent groups.
  • nucleic acids described herein include one or more bicyclic nucleic acids.
  • the bicyclic nucleic acid comprises a bridge between the 4’ and the 2’ ribosyl ring atoms.
  • nucleic acids provided herein include one or more bicyclic nucleic acids wherein the bridge comprises a 4’ to 2’ bicyclic nucleic acid.
  • Examples of such 4’ to 2’ bicyclic nucleic acids include, but are not limited to, one of the formulae: 4’-(CH 2 )-O-2’ (LNA); 4’-(CH 2 )-S-2’; 4’-(CH 2 ) 2 -O-2’ (ENA); 4’-CH(CH 3 )-O- 2’ and 4’-CH(CH 2 OCH 3 )-O-2’, and analogs thereof (see, U.S. PatentNo. 7,399,845); 4’- C(CH 3 )(CH 3 )-O-2’and analogs thereof, (see WO2009/006478, W02008/150729, US2004/0171570, U.S. PatentNo.
  • nucleic acids comprise linked nucleic acids.
  • Nucleic acids can be linked together using any inter nucleic acid linkage.
  • the two main classes of inter nucleic acid linking groups are defined by the presence or absence of a phosphorus atom.
  • Non -phosphorus containing inter nucleic acid linking groups include, but are not limited to, methylenemethylimino (-CH 2 -N(CH 3 )-O-CH 2 -), thiodiester (-O-C(O)-S-), thionocarbamate (-O-C(O)(NH)-S-); siloxane (-O-Si(H) 2 -O-); and N,N* -dimethylhydrazine (-CH 2 -N(CH 3 )-N(CH 3 )).
  • inter nucleic acids linkages having a chiral atom can be prepared as a racemic mixture, as separate enantiomers, e.g., alkylphosphonates and phosphorothioates.
  • Unnatural nucleic acids can contain a single modification.
  • Unnatural nucleic acids can contain multiple modifications within one of the moieties or between different moieties.
  • Backbone phosphate modifications to nucleic acid include, but are not limited to, methyl phosphonate, phosphorothioate, phosphoramidate (bridging or non -bridging), phosphotriester, phosphorodithioate, phosphodithio ate, and boranophosphate, and may be used in any combination. Other non- phosphate linkages may also be used.
  • backbone modifications e.g., methylphosphonate, phosphorothioate, phosph oroamidate and phosph orodithioate internucleotide linkages
  • a phosphorous derivative is attached to the sugar or sugar analog moiety and can be a monophosphate, diphosphate, triphosphate, alkylphosphonate, phosphorothioate, phosphorodithioate, phosphoramidate or the like.
  • Exemplary polynucleotides containing modified phosphate linkages or non-phosphate linkages can be found in Peyrottes etal., 1996, Nucleic Acids Res. 24: 1841-1848; Chaturvedi etal., 1996, Nucleic Acids Res. 24:2318-2323; and Schultz etal., (1996) Nucleic Acids Res.
  • backbone modification comprises replacing the phosphodiester linkage with an alternative moiety such as an anionic, neutral or cationic group.
  • modifications include: anionic internucleoside linkage; N3’ to P5’ phosphoramidate modification; boranophosphate DNA; prooligonucleotides; neutral internucleoside linkages such as methylphosphonates; amide linked DNA; methylene(methylimino) linkages; formacetal and thioformacetal linkages; backbones containing sulfonyl groups; morpholino oligos; peptide nucleic acids (PNA); and positively charged deoxyribonucleic guanidine (DNG) oligos (Micklefield, 2001, Current Medicinal Chemistry 8: 1157-1179).
  • a modified nucleic acid may comprise a chimeric or mixed backbone comprising one or more modifications, e.g. a combination of phosphate linkages such as a combination of phosphodiester and
  • Substitutes for the phosphate include, for example, short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
  • morpholino linkages formed in part from the sugar portion of a nucleoside
  • siloxane backbones sulfide, sulfoxide and sulfone backbones
  • formacetyl and thioformacetyl backbones methylene formacetyl and thioformacetyl backbones
  • alkene containing backbones sulfamate backbones
  • sulfonate and sulfonamide backbones amide backbones; and others having mixed N, O, S and CH 2 component parts.
  • Conjugates can be chemically linked to the nucleotide or nucleotide analogs.
  • Such conjugates include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. KY. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med.
  • lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et
  • Acids Res., 1990, 18, 3777-3783 a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651 -3654), a palmityl moiety (Mishra et al., Biochem. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino- carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp.
  • a polynucleotide (also referred to as a nucleic acid) comprising an unnatural ribonucleotide is from any source or composition, such as DNA, cDNA, gDNA (genomic DNA), RNA, siRNA (short inhibitory RNA), RNAi, tRNA, mRNA or rRNA (ribosomal RNA), for example, and is in any form (e.g., linear, circular, supercoiled, singlestranded, double-stranded, and the like).
  • nucleic acids comprise nucleotides, nucleosides, or polynucleotides. In some cases, nucleic acids comprise natural and unnatural nucleic acids.
  • a nucleic acid also comprises unnatural nucleic acids, such as DNA or RNA analogs (e.g., containing nucleobase analogs, sugar analogs and/or a nonnative backbone and the like). It is understood that the term “nucleic acid” does not refer to or infer a specific length of the polynucleotide chain, thus polynucleotides and oligonucleotides are also included in the definition.
  • a nucleic acid sometimes is a vector, plasmid, phage mid, autonomously replicating sequence (ARS), centromere, artificial chromosome, yeast artificial chromosome (e.g., YAC) or other nucleic acid able to replicate or be replicated in a host cell.
  • an unnatural nucleic acid is a nucleic acid analogue.
  • an unnatural nucleic acid is from an extracellular source.
  • an unnatural nucleic acid is available to the intracellular space of an organism provided herein, e.g., a genetically modified organism.
  • an unnatural nucleotide is not a natural nucleotide.
  • a nucleotide that does not comprise a natural nucleobase comprises an unnatural nucleobase.
  • polynucleotides are used as a substrate for an reverse transcriptase or synthesized by a reverse transcriptase comprising natural nucleotides in addition to at least one unnatural nucleotide.
  • natural nucleotides include, without limitation, ATP, UTP, CTP, GTP, ADP, UDP, CDP, GDP, AMP, UMP, CMP, GMP, dATP, dTTP, dCTP, dGTP, dADP, dTDP, dCDP, dGDP, dAMP, dTMP, dCMP, and dGMP.
  • Exemplary natural deoxyribonucleotides include dATP, dTTP, dCTP, dGTP, dADP, dTDP, dCDP, dGDP, dAMP, dTMP, dCMP, and dGMP.
  • Exemplary natural ribonucleotides include ATP, UTP, CTP, GTP, ADP, UDP, CDP, GDP, AMP, UMP, CMP, and GMP. It is understood that triphosphate forms of nucleotides are the substrate for polymerization, and that upon addition to a nascent polynucleotide chain the nucleotide is converted to a nucleotide of the monophosphate form.
  • a nucleotide analog, or unnatural nucleotide comprises a nucleotide which contains some type of modification to either the nucleobase, sugar, or phosphate moieties.
  • a modification comprises a chemical modification.
  • modifications occur at the 3 ’OH or 5 ’OH group, at the backbone, at the sugar component, or at the nucleobase.
  • the modified nucleic acid comprises modification of one or more of the 3 ’OH or 5 ’OH group, the backbone, the sugar component, or the nucleobase, and /or addition of non-naturally occurring linker molecules.
  • a modified backbone comprises a backbone other than a phosphodiester backbone.
  • a modified sugar comprises a sugar other than deoxyribose (in modified DNA) or other than ribose (modified RNA).
  • a modified nucleobase comprises a nucleobase other than adenine, guanine, cytosine or thymine (in modified DNA) or a nucleobase other than adenine, guanine, cytosine or uracil (in modified RNA).
  • the nucleic acid comprises at least one modified nucleobase.
  • the nucleic acid comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more modified nucleobases.
  • modifications to the nucleobase moiety include natural and synthetic modifications of A, C, G, and T/U as well as different purine or pyrimidine nucleobases.
  • a modification is to a modified form of adenine, guanine cytosine or thymine (in modified DNA) or a modified form of adenine, guanine cytosine or uracil (modified RNA).
  • the modified nucleobase may be any of the modified nucleobases specifically described elsewhere herein.
  • the reverse transcriptase produces full-length cDNA.
  • the reverse transcriptase produces cDNA that comprises a nucleotide in the position complementary to the unnatural ribonucleotide in the polynucleotide undergoing reverse transcription and a plurality of nucleotides 3 ’ of the nucleotide in the position complementary to the unnatural ribonucleotide (e.g., at least 2, 5, 10, or 20 nucleotides) and includes cDNA that is fully complementary to the polynucleotide undergoing reverse transcription.
  • the cDNA comprises at least 90%, 95%, 97%, or 99% as many nucleotides as the polynucleotide undergoing reverse transcription. In some embodiments, the cDNA is fully complementary to the polynucleotide undergoing reverse transcription. In some embodiments, at least 25% of the cDNA comprises the unnatural nucleobase. In some embodiments, at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% of the cDNA comprises the unnatural nucleobase.
  • an unnatural nucleotide forms a base pair (an unnatural base pair; UBP) with another unnatural nucleotide during and/or after incorporation, e.g., by a reverse transcriptase.
  • a stably integrated unnatural nucleotide is an unnatural nucleotide that can form a base pair with another nucleotide, e.g., a natural or unnatural nucleotide.
  • a stably integrated unnatural nucleotide is an unnatural nucleotide that can form a base pair with another unnatural nucleotide (unnatural base pair (UBP)).
  • a firstunnatural nucleotide can form a base pair with a second unnatural nucleotide.
  • one pair of unnatural nucleoside triphosphates that can base pair during and/or after incorporation into nucleic acids include a triphosphate of (d)5 SICS ((d)5 SICSTP) and a triphosphate of (d)NaM ((d)NaMTP).
  • Other examples include but are not limited to: a triphosphate of (d)CNMO ((d)CNMOTP) and a triphosphate of (d)TPT3 ((d)TPT3TP).
  • unnatural nucleotides can have a ribose or deoxyribose sugar moiety (indicated by the “(d) ”).
  • one pair of unnatural nucleoside triphosphates that can base pair when incorporated into nucleic acids includes a triphosphate of (d)TATl ((d)TATlTP) and a triphosphate of (d)NaM ((d)NaMTP).
  • one pair of unnatural nucleoside triphosphates that can base pair when incorporated into nucleic acids includes a triphosphate of (d)CNMO ((d)CNMOTP) and a triphosphate of (d)TATl ((d)TATlTP).
  • one pair of unnatural nucleoside triphosphates that can base pair when incorporated into nucleic acids includes a triphosphate of (d)TPT3 ((d)TPT3TP) and a triphosphate of (d)NaM ((d)NaMTP).
  • an unnatural nucleotide does not substantially form a base pair with a natural nucleotide (A, T, G, C, U).
  • a stably integrated unnatural nucleotide can form a base pair with a natural nucleotide.
  • a stably integrated unnatural (deoxy )ribonucleotide is an unnatural (deoxy )ribonucleotide that can form a UBP but does not substantially form a base pair with each any of the natural (deoxy )ribonucleoti des.
  • a stably integrated unnatural (deoxy )ribonucleotide is an unnatural (deoxy)ribonucleotide that can form a UBP but does not substantially form a base pair with one or more natural nucleic acids.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with A, T, and, C, but can form a base pair with G.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with A, T, and, G, but can form a base pair with C.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with C, G, and, A, but can form a base pair with T.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with C, G, and, T, but can form a base pair with A.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with A and T, but can form a base pair with C and G.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with A and C, but can form a base pair with T and G.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with A and G, but can form a base pair with C and T.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with C and T, but can form a base pair with A and G.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with C and G, but can form a base pair with T and G.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with T and G, but can form a base pair with A and G.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with, G, but can form a base pair with A, T, and, C.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with, A, but can form a base pair with G, T, and, C.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with, T, but can form abase pair with G, A, and, C.
  • a stably integrated unnatural nucleotide may not substantially form a base pair with, C, but can form a base pair with G, T, and, A.
  • unnatural nucleotides capable of forming an unnatural DNA or RNA base pair(UBP) include, but are not limited to, (d)5SICS, (d)5SICS, (d)NaM, (d)NaM, (d)TPT3, (d)MTMO, (d)CNMO, (d)TATl, and combinations thereof.
  • unnatural nucleotide base pairs include but are not limited to:
  • aUBP is formed wherein the unnatural nucleobases are as shown above or described elsewhere herein and one of the sugars is a ribose or a modified form thereof (but is not deoxyribose).
  • methods disclosed herein comprise measuring the amount of an unnatural nucleotide, e.g., in a cDNA.
  • the cDNA was produced from an RNA transcribed from a DNA molecule, such an approach can be used to determine, independently of translation, a lower bound for the fidelity of retention of an unnatural nucleotide during transcription.
  • the method is for measuring combined fidelity of transcription and reverse transcription.
  • the method is for measuring retention of an unnatural nucleotide during transcription and reverse transcription.
  • the measuring step can use a binding partner can be used that recognizes an unnatural nucleobase.
  • the binding partner can be a biotin -binding agent (e.g., streptavidin, avidin, Neutravidin, or an anti-biotin antibody).
  • the biotin-binding agent is associated with (e.g., bound to, such as covalently) a solid support, such as beads.
  • the binding partner is streptavidin.
  • Binding of the binding partner can be assessed in a gel shift assay or mobility shift assay, in that polynucleotide bound to the binding partner (understood to comprise the unnatural nucleobase) will exhibit a different electrophoretic mobility than unbound polynucleotide (understood to lack the unnatural nucleobase).
  • a binding partner can still be used to measure the amount of the unnatural nucleobase, e.g., as follows.
  • a complementary molecule or amplicon can be generated from the cDNA (e.g., as described for biotin shift assays performed in the Examples) that does comprise a biotinylated unnatural nucleobase, which can then be assayed as a proxy for the cDNA, with appropriate adjustments in the calculations.
  • the amplification of the cDNA is by PCR.
  • Exemplary biotinylated unnatural nucleobases can be incorporated in the complementary molecule or amplicon using dMMO2bioTP (a biotinylated analog of dNaMTP) and d5 SICSTP (an analog of dTPT3 TP that pairs with dMMO2bio during replication better than dTPT3TP itself.
  • measuring the amount of the unnatural nucleotide in the cDNA using a binding partner that recognizes an unnatural nucleobase comprises a biotin shift assay.
  • a biotin shift assay encompasses any assay that distinguishes biotinylated from unbiotinylated products on the basis of differential mobility binding or not binding to a biotin -binding agent such as streptavidin.
  • the mobility may be, for example, electrophoretic mobility (e.g., gel electrophoretic mobility or capillary electrophoretic mobility) or chromatographic mobility (e.g., using gel filtration, ion exchange, or hydrophobic interaction chromatography).
  • the transcription may be in vitro or in vivo.
  • the transcription is in a bacterium or prokaryote, such as E. colt.
  • the DNA molecule from which the RNA is transcribed is an ssDNA or dsDNA.
  • the method comprises calculating transcription-reverse transcription (T-RT) fidelity (the overall fidelity of transcription and reverse transcription steps).
  • T-RT fidelity can be determined as a ratio of (a) the proportion of cDNA that contains unnatural nucleotide to (b) the proportion of DNA before transcription that contains the unnatural nucleotide.
  • a further synthesis step such as an amplification is used to prepare biotinylated DNA
  • the ratio can be adjusted by a factor to compensate for unnatural base pair loss in the further synthesis step.
  • 1 .06 is an exemplary value for the factor.
  • the methods comprise incubating a plurality of different RNA oligonucleotides (a “library”) with a target, wherein the RNA oligonucleotides comprise at least one unnatural nucleotide.
  • the methods comprise performing at least one round of selection for RNA oligonucleotides of the plurality that bind to the target.
  • the methods comprise isolating enriched RNA oligonucleotides that bind to the target, wherein the isolated enriched RNA oligonucleotides comprise RNA aptamers.
  • the methods comprise reverse transcribing one or more of the RNA aptamers into cDNAs, wherein the cDNAs comprise an unnatural deoxyribonucleotide at the position complementary to the unnatural nucleobase in the RNA aptamer, thereby providing a library of cDNA molecules corresponding to the RNA aptamers.
  • the plurality of different RNA oligonucleotides comprise a randomized nucleotide region. This can be generated, e.g., using mixed pools of nucleotides in certain cycles of a nucleotide synthesis procedure or by performing mutagenic PCR before transcribing oligonucleotides from DNA templates.
  • the randomized nucleotide region may comprise one or a plurality of randomized positions. Where there is a plurality of randomized positions, they may be consecutive or interrupted by one or more nonrandomized nucleotides or segments of nonrandomized nucleotides.
  • the unnatural nucleobase is within the randomized region (e.g., 3 ’ to a first randomized position and 5 ’ to a second randomized position). In some embodiments, the unnatural nucleobase is within 5 or 10 nucleotides of at least one randomized position. In some embodiments, the unnatural nucleobase is immediately adjacent to a randomized position, oris immediately adjacent to two randomized positions.
  • the RNA oligonucleotides comprise barcode sequences and/or primer binding sequences. As illustrated in Example 7, barcode sequences can be used to identify the position of the unnatural nucleobase, and primer binding sequences can be used for downstream analysis of active sequences following selection.
  • cDNAs produced from the RNA aptamers are sequenced.
  • cDNAs produced from the RNA aptamers are mutated to generate a plurality of additional sequences, which canthen be transcribed into RNA to perform at least one further round of selection. Mutating the cDNAs can be performed, e.g., by error-prone PCR.
  • the selection comprises a wash step to remove unbound or weakly bound RNA oligonucleotides. A series of wash steps maybe employed where stringency increases, e.g., to provide more selection pressure as the method proceeds.
  • RNA aptamers identified by the method may be analyzed, e.g., individually, fortheir ability to bind, agonize, or antagonize the target.
  • analyzing the RNA aptamers for their ability to bind the target comprises determining a K& k on , or k o s.
  • analyzing the RNA aptamers for their ability to agonize the target comprises determining an EC 50 value.
  • analyzing the RNA aptamers for their ability to antagonize the target comprises determining a K[ or IC 50 value.
  • a polynucleotide comprising an unnatural ribonucleotide comprises at least 15 nucleotides. In some embodiments, the polynucleotide comprises at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, or 100 nucleotides. In some embodiments, a polynucleotide comprising an unnatural ribonucleotide comprises one or more ORFs.
  • An ORF may be from any suitable source, sometimes from genomic DNA, mRNA, reverse transcribed RNA or complementary DNA (cDNA) or a nucleic acid library comprising one or more of the foregoing and is from any organism species that contains a nucleic acid sequence of interest, protein of interest, or activity of interest.
  • organisms from which an ORF can be obtained include bacteria, yeast, fungi, human, insect, nematode, bovine, equine, canine, feline, rat or mouse, for example.
  • a nucleotide and/or nucleic acid reagent or other reagent described herein is isolated or purified. ORFs may be created that include unnatural nucleotides via published in vitro methods.
  • a nucleotide or nucleic acid reagent comprises an unnatural nucleobase.
  • a polynucleotide sometimes comprises a nucleotide sequence adjacent to an ORF that is translated in conjunction with the ORF and encodes an amino acid tag.
  • the tag-encoding nucleotide sequence is located 3 ’ and/or 5 ’ of an ORF in the nucleic acid reagent, thereby encoding a tag at the C-terminus or N-terminus of the protein or peptide encoded by the ORF. Any tag that does not abrogate in vitro transcription and/or translation may be utilized and may be appropriately selected by the artisan. Tags may facilitate isolation and/or purification of the desired ORF product from culture or fermentation media.
  • libraries of nucleic acid reagents are used with the methods and compositions described herein. For example, a library of atleast 100, 1000, 2000, 5000, 10,000, or more than 50,000 unique polynucleotides are present in a library, wherein each polynucleotide comprises at least one unnatural nucleobase.
  • a polynucleotide can comprise certain elements, e.g., regulatory elements, often selected according to the intended use of the nucleic acid. Any of the following elements can be included in or excluded from a nucleic acid reagent.
  • a polynucleotide may include one or more or all of the following nucleotide elements: one or more promoter elements, one or more 5 ’ untranslated regions (5 ’UTRs), one or more regions into which a target nucleotide sequence may be inserted (an “insertion element”), one or more target nucleotide sequences, one or more 3 ’ untranslated regions (3 ’UTRs), and one or more selection elements.
  • a polynucleotide can be provided with one or more of such elements and other elements may be inserted into the nucleic acid before the nucleic acid is introduced into the desired organism.
  • a provided nucleic acid reagent comprises a promoter, a 5 ’UTR, an optional 3 ’UTR and insertion element(s) by which a target nucleotide sequence is inserted (i.e., cloned) into the nucleotide acid reagent.
  • a provided nucleic acid reagent comprises a promoter, insertion element(s) and optional 3 ’UTR, and a 5 ’ UTR/target nucleotide sequence is inserted with an optional 3 ’UTR.
  • the elements can be arranged in any order suitable for expression in the chosen expression system (e.g., expression in a chosen organism, or expression in a cell-free system, for example), and in some embodiments a nucleic acid reagent comprises the following elements in the 5’ to 3’ direction: (1) promoter element, 5’UTR, and insertion element(s); (2) promoter element, 5’UTR, and target nucleotide sequence; (3) promoter element, 5’UTR, insertion element(s) and 3 ’UTR; and (4) promoter element, 5’UTR, target nucleotide sequence and 3 ’UTR.
  • the UTR can be optimized to alter or increase transcription or translation of the ORF that are either fully natural or that contain unnatural nucleotides.
  • Polynucleotides can include a variety of regulatory elements, including promoters, enhancers, translational initiation sequences, transcription termination sequences and other elements.
  • a “promoter” is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site.
  • the promoter can be upstream of the nucleotide triphosphate transporter nucleic acid segment.
  • a “promoter” contains core elements required for basic interaction of RNA polymerase and transcription factors and can contain upstream elements and response elements.
  • Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5 ’ or 3 ” to the transcription unit. Furthermore, enhancers can be within an intron as well as within the coding sequence itself. They are usually between 10 and 300 nucleotides in length, and they can function in cis. Enhancers function to increase transcription from nearby promoters. Enhancers, like promoters, also often contain response elements that mediate the regulation of transcription. Enhancers often determine the regulation of expression and can be used to alter or optimize ORF expression, including ORFs that are fully natural or that contain unnatural nucleotides.
  • a polynucleotide may also comprise one or more 5’ UTR’s, and one or more 3 ’UTR’s.
  • expression vectors used in eukaryotic host cells e.g., yeast, fungi, insect, plant, animal, human or nucleated cells
  • prokaryotic host cells e.g., virus, bacterium
  • eukaryotic host cells e.g., yeast, fungi, insect, plant, animal, human or nucleated cells
  • prokaryotic host cells e.g., virus, bacterium
  • a transcription unit comprises a poly adenylation region.
  • a 5 ’ UTR may comprise one or more elements endogenous to the nucleotide sequence from which it originates, and sometimes includes one or more exogenous elements.
  • a 5’ UTR can originate from any suitable nucleic acid, such as genomic DNA, plasmid DNA, RNA or mRNA, for example, from any suitable organism (e.g., virus, bacterium, yeast, fungi, plant, insect or mammal).
  • a 5 ’ UTR sometimes comprises one or more of the following elements known to the artisan: enhancer sequences (e.g., transcriptional or translational), transcription initiation site, transcription factor binding site, translation regulation site, translation initiation site, translation factor binding site, accessory protein binding site, feedback regulation agent binding sites, Pribnowbox, TATA box, -35 element, E-box (helix-loop-helix binding element), ribosome binding site, replicon, internal ribosome entry site (IRES), silencer element and the like.
  • a promoter element may be isolated such that all 5 ’ UTR elements necessary for proper conditional regulation are contained in the promoter element fragment, or within a functional subsequence of a promoter element fragment.
  • a 5 ‘ UTR in the polynucleotide can comprise a translational enhancer nucleotide sequence.
  • a translational enhancer nucleotide sequence often is located between the promoter and the target nucleotide sequence in a polynucleotide.
  • a translational enhancer sequence often binds to a ribosome, sometimes is an 18S rRNA-binding ribonucleotide sequence (i.e., a 40S ribosome binding sequence) and sometimes is an internal ribosome entry sequence (IRES).
  • An IRES generally forms an RNA scaffold with precisely placed RNA tertiary structures that contact a 40S ribosomal subunit via a number of specific intermolecular interactions.
  • ribosomal enhancer sequences are known and can be identified by the artisan (e.g., Mumblee et al., Nucleic Acids Research 33 : D141 -D146 (2005); Paulous et al., Nucleic Acids Research 31 : 722-733 (2003); Akbergenov et al., Nucleic Acids Research 32: 239-247 (2004); Mignone et al., Genome Biology 3(3): reviews0004.1 -0001.10 (2002); Gallie, Nucleic Acids Research 30: 3401-3411 (2002); Shaloiko et al., DOI: 10.1002/bit.20267; and Gallie et al., Nucleic Acids Research 15: 3257-3273 (1987)).
  • a translational enhancer sequence sometimes is a eukaryotic sequence, such as a Kozak consensus sequence or other sequence (e.g., hydroid polyp sequence, GenBank accession no. U07128).
  • a translational enhancer sequence sometimes is a prokaryotic sequence, such as a Shine-Dalgarno consensus sequence.
  • the translational enhancer sequence is a viral nucleotide sequence.
  • a translational enhancer sequence sometimes is from a 5’ UTR of a plant virus, such as Tobacco Mosaic Virus (TMV), Alfalfa Mosaic Virus (AMV); Tobacco Etch Virus (ETV); Potato Virus Y (PVY); Turnip Mosaic (poty) Virus and Pea Seed Borne Mosaic Virus, for example.
  • TMV Tobacco Mosaic Virus
  • AMV Alfalfa Mosaic Virus
  • ETV Tobacco Etch Virus
  • PVY Potato Virus Y
  • Turnip Mosaic (poty) Virus and Pea Seed Borne Mosaic Virus for example.
  • an omega sequence about 67 basesin length from TMV is included in the polynucleotide as a translational enhancer sequence (e.g., devoid of guanosine nucleotides and includes a 25-nucleotide long poly (CAA) central region).
  • CAA 25-nucleotide
  • a 3 ’ UTR may comprise one or more elements endogenous to the nucleotide sequence from which it originates and sometimes includes one or more exogenous elements.
  • a 3 ’ UTR may originate from any suitable nucleic acid, such as genomic DNA, plasmid DNA, RNA or mRNA, for example, from any suitable organism (e.g., a virus, bacterium, yeast, fungi, plant, insect or mammal). The artisan can select appropriate elements for the 3’ UTR based upon the chosen expression system (e.g., expression in a chosen organism, for example).
  • a 3’ UTR sometimes comprises one or more of the following elements known to the artisan: transcription regulation site, transcription initiation site, transcription termination site, transcription factor binding site, translation regulation site, translation termination site, translation initiation site, translation factor binding site, ribosome binding site, replicon, enhancer element, silencer element and polyadenosinetail.
  • a 3 ’ UTR often includes a poly adenosine tail and sometimes does not, and if a polyadenosinetail is present, one or more adenosine moieties may be added or deleted from it (e.g., about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45 or about 50 adenosine moieties may be added or subtracted).
  • modification of a 5’ UTR and/or a 3 ’ UTR is used to alter (e.g., increase, add, decrease or substantially eliminate) the activity of a promoter.
  • Alteration of the promoter activity can in turn alter the activity of a peptide, polypeptide or protein (e.g., enzyme activity for example), by a change in transcription of the nucleotide sequence(s) of interest from an operably linked promoter element comprising the modified 5’ or 3 ’ UTR.
  • a microorganism can be engineered by genetic modification to express a polynucleotide comprising a modified 5’ or 3 ’ UTR that can add a novel activity (e.g., an activity not normally found in the host organism) or increase the expression of an existing activity by increasing transcription from a homologous or heterologous promoter operably linked to a nucleotide sequence of interest (e.g., homologous or heterologous nucleotide sequence of interest), in certain embodiments.
  • a novel activity e.g., an activity not normally found in the host organism
  • a nucleotide sequence of interest e.g., homologous or heterologous nucleotide sequence of interest
  • a microorganism can be engineered by genetic modification to express a nucleic acid reagent comprising a modified 5 ’ or 3 ’ UTR that can decrease the expression of an activity by decreasing or substantially eliminating transcription from a homologous or heterologous promoter operably linked to a nucleotide sequence of interest, in certain embodiments.
  • kits and articles of manufacture for use with one or more methods described herein.
  • Such kits include a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein.
  • Suitable containers include, for example, bottles, vials, syringes, and test tubes.
  • the containers are formed from a variety of materials such as glass or plastic.
  • a kit includes a suitable packaging material to house the contents of the kit.
  • the packaging material is constructed by well-known methods, preferably to provide a sterile, contaminant-free environment.
  • the packaging materials employed herein can include, for example, those customarily utilized in commercial kits sold for use with nucleic acid sequencing systems.
  • Exemplary packaging materials include, without limitation, glass, plastic, paper, foil, and the like, capable of holding within fixed limits a component set forth herein.
  • the packaging material can include a label which indicates a particular use for the components.
  • the use for the kit that is indicated by the label can be one or more of the methods set forth herein as appropriate for the particular combination of components present in the kit.
  • a label can indicate that the kit is useful for a method of synthesizing a polynucleotide or for a method of determining the sequence of a nucleic acid.
  • kits Instructions for use of the packaged reagents or components can also be included in a kit.
  • the instructions will typically include a tangible expression describing reaction parameters, such as the relative amounts of kit components and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions, and the like.
  • kits can identify the additional component(s) that are to be provided and where they can be obtained.
  • kits are provided that is useful for stably incorporating an unnatural nucleic acid into a cellular nucleic acid, e.g., using the methods provided by the present disclosure for preparing genetically engineered cells.
  • a kit described herein includes a genetically engineered cell and one or more unnatural nucleic acids.
  • the kit described herein provides a cell and a nucleic acid molecule containing a heterologous gene for introduction into the cell to thereby provide a genetically engineered cell, such as expression vectors comprising the nucleic acid of any of the embodiments hereinabove describedin this paragraph.
  • Nucleosides of dNaM, dTPT3, NAM, TPT3, d5SICS and dMMO2 bio were synthesized (WuXi AppTec; Shanghai, China) and triphosphorylated (TriLink BioTechnologies LLC; San Diego, CA and MyChem LLC; San Diego, CA) commercially. All unnatural oligonucleotides were synthesized and HPLC purified by Biosearch Technologies (Petaluma, CA). All DNA samples containing the unnatural base pair were stored at -20 °C. All RNA samples were stored at -80 °C.
  • Table 4 discloses SEQ ID NOS 1 -12, respectively, in order of appearance.
  • Table 5 discloses SEQ ID NOS 13-34, respectively, in order of appearance.
  • EGFP and tRNA templates Construction of EGFP and tRNA templates.
  • the inserts used in all Golden Gate assemblies were PCR products generated with synthesized dNaM-containing oligonucleotides and primers YZ73 and YZ74 (Table 6). Plasmids pUCCS2_EGFP(NNN) and pUCCYBA_EGFP(NNN) were purified after Golden Gate assembly and quantified using Qubit (ThermoFisher).
  • EGFP template plasmids (2 ng) were used in the template -generating PCR reaction with primers EDI 01 and AZ38 for pUCCS2_EGFP(NNN), and primers ED 101 and AZ87 for pUCCYBA_EGFP(NNN).
  • the PCR products were subjected to Dpnl digestion and then purified to yield EGFP templates for in vitro transcription.
  • tRNA templates were made by direct PCR from synthesized dNaM-containing oligonucleotides with primers AZ01 and AZ67. The PCR products were purified to yield tRNA templates for in vitro transcription.
  • the pSyn_sfGFP(NNN)_mm(NNN) plasmids used in SSO in vivo translation experiments were made by Golden Gate assembly.
  • the inserts used in all Golden Gate assemblies were PCR products generated with synthesized dNaM-containing oligonucleotides either with primer set YZ73/YZ74 for mRNA codon insert or primer set YZ435/YZ436 for tRNA anticodon insert.
  • Plasmids pSyn_sfGFP(NNN)_mm(NNN) was purified after Golden Gate assembly and quantified using Qubit.
  • Biotin shift assay The retention ofthe unnatural base pair in templates ofRNA species were assayed using d5 SICSTP and dMMO2bio-TP with a corresponding primer set. Band intensities were quantified using Image Lab (Bio-Rad). Unnatural base pair retention was normalized by dividing the percentage raw shift of each sample by the percentage raw shift of the synthesized dNaM-containing oligonucleotide template used in the Golden Gate assembly when constructing the EGFP plasmid. Biotin shift assays are discussed in detail in Malyshev et al., A Semi-Synthetic Organism with an Expanded Genetic Alphabet. Nature 2014, 509, 385— 388.
  • RNA loading dye B0363S, New England Biolabs, (NEB)
  • 8 Murea 8 Murea
  • the other 10 ⁇ L of the reaction mixture was purified using a commercial RNA purification kit(D7011, Zymo Research; Irvine, CA) and the product cDNA was quantified using Qubit.
  • the asDNA was prepared via PCR amplification with a biotinylated 5’ primer from the dsDNA template used for the IVT reaction.
  • the product biotinylated dsDNA was subjected to affinity single-strand isolation protocol using DynabeadsTM MyOneTM Streptavidin Cl (65001, ThermoFisher) according to the manufacturer instruction. Briefly, beads (20 ⁇ L) were pre-washed 3 times with WB buffer and then mixed with purified bio-dsDNA (20 ⁇ L, ⁇ 50 ng/ ⁇ L). The mixture was incubated for 2 h at 37 °C with gentle shaking. The beads were separated from the buffer using a magnetic stand.
  • the beads were then washed 3 times with WB buffer, and the unbiotinylated strand was eluted using 100 ⁇ L 0.1 M NaOH (wash time ⁇ 30 s). The eluted unbiotinylated asDNA was then purified using column purification.
  • the culture was rapidly cooled in an ice water bath for 5 min with shaking, and then pelleted at 3, 200 *g for 10 min. Cells were next washed twice with one culture volume of prechilled autoclaved Milli-Q H2O. Cells were then resuspended in additional chilled H 2 O, to an OD600 of 50 - 60. For each sample tested, 50 ⁇ L of the resulting electrocompetent cells were combined with 0.5 ng of Golden Gate assembled plasmid containing the UBP embedded within the sfGFP and tRNA pyl genes and then transferred to a pre-chilled electroporation cuvette (0.2 cm gap).
  • Cells were electroporated (Gene Pulser II; Bio-Rad) according to the manufacturer’s instructions for bacteria (25 kV, 2.5 pF, and 200 Q resistor), then immediately diluted with 950 ⁇ L of pre-warmed media. 10 ⁇ L of this dilution was then diluted with pre-warmed media to a final volume of 50 ⁇ L, supplemented with 150 mM dNaMTP and 10 ⁇ M dTPT3TP. The transformation was allowed to recover at 37 °C for 1 h.
  • the recovery culture was plated on solid media supplemented with 50 pg/mL zeocin (R25001, ThermoFisher), 150 ⁇ MdNaMTP, 10 ⁇ M dTPT3TP, and 2% w/v agar, then allowed to grow at 37 °C overnight.
  • zeocin R25001, ThermoFisher
  • 150 ⁇ MdNaMTP, 10 ⁇ M dTPT3TP 2% w/v agar
  • Colonies that were shown to have retained the UBP were then diluted back to an OD600 of - 0.1 - 0.2 in 300 ⁇ L growth media supplemented with 150 ⁇ MdNaMTP, and 10 ⁇ MdTPT3TP.
  • OD600 0.4-0.6
  • cultures were supplemented with 250 ⁇ MNaMTP and 30 ⁇ M TPT3TP unless stated otherwise, as well as 10 mM of the ncAAN6-(2-azidoethoxy)-carbonyl-L-lysine (AzK).
  • the culture was then grown for and additional 20 min before adding IPTG (CAS 367 -93-1, Sigma Aldrich) to a concentration of 1 mM and grown for 1 h to induce the transcription of the T7 RNA polymerase, the tRNAN 1 , and the PylRS.
  • IPTG CAS 367 -93-1, Sigma Aldrich
  • Cells were monitored for growth (OD600) and GFP fluorescence every 30 min.
  • Expression of sfGFP was then induced with 100 ng/mL anhydrotetracycline (CAS 13803-65-1, Sigma Aldrich). After an additional 3 h of growth, cell cultures were collected and cooled on ice. 50 ⁇ L of the culture was used for plasmid isolation to determine UBP retention (biotin shift assay); the remaining 250 ⁇ L of the culture was used for total RNA extraction to measure T-RT retention.
  • RNA extraction Following the in vivo translation experiment, the E. coli culture was collected and centrifuged (Centrifuge 5415 C, Eppendorf) at 10,000 rpm for 30 seconds, and the supernatant was discarded. 1 mL TRIzol (15596026, ThermoFisher) was then added to each sample. The mixture was homogenized and incubated at room temperature for 5 min. 200 ⁇ L chloroform (CAS 67-66-3, Sigma Aldrich) was added to each sample and the mixture was vortexed to homogenization, followed by room temperature incubation for 3 min to allow for phase separation.
  • the sample was centrifuged at 12,000 rpm for 15 min at 4 °C, the colorless aqueous phase was collected into a new tube and 500 ⁇ L isopropyl alcohol (CAS 67- 63-0, Sigma Aldrich) was added to the aqueous phase. After incubation at room temperature for 10 min, the sample was centrifuged at 7,000 rpm for 10 min at 4 °C and the supernatant was discarded. The sample was then washed with 2 ' 1 mL 75% ethanol. The lids of the tubes were kept open to allow the sample to dry for 30 min at room temperature, and the resulting total RNA was dissolved with 20 ⁇ L RNase-free water. The concentration of the total RNA was measured using Qubit.
  • RNA was purified and then used as a template for RT reactions that were performed with or without unnatural deoxyribonucleoside triphosphate (in addition, the primer installed a 3 ’ - extension to facilitate analysis, see foil owing paragraph). After 1 hour, half of the RT reaction was subjected to PAGE gel electrophoresis to qualitatively assess the presence of full length and truncated products, and the other half was purified for subsequent characterization of the retention of the unnatural nucleotide.
  • RNA templates containing either NaM or TPT3 yielded mostly only truncated cDNA product when dTPT3TP or dNaMTP was absent, and mostly only full-length product when dTPT3TP or dNaMTP was provided (FIG. 2).
  • SuperScript III or SuperScriptIV full length cDNA product was observed with either template regardless of whether the unnatural triphosphates were added (FIG. 2).
  • a biotin shift assay performed essentially as described in Malyshev et al., A Semi-Synthetic Organism with an Expanded Genetic Alphabet.
  • PCR products were then incubated with streptavidin and subjected to PAGE electrophoresis, where the resulting ratio of shifted to unshifted bands indicates the percentage of the cDNA that contains an unnatural nucleotide.
  • unnatural triphosphates were withheld from the RT reaction, no shifted products were observed.
  • the complementary unnatural triphosphate was added to the RT reaction, a substantial shift was observed, indicating that with all three reverse transcriptases, a significant amount of the cDNA product contained the unnatural nucleotide (FIG. 2).
  • tRNA templates produced by IVT of PCR products from synthetic oligonucleotides containing dNaM or dTPT3 at positions corresponding to the second nucleotide of the anticodon were used to study the effect of tRNA template concentration on efficiency of reverse transcription of unnatural nucleobases.
  • tRNA template concentration 25 ng/ ⁇ L
  • the percentage of full-length product increased.
  • With 0.5 pg/mL template reverse transcription resulted in 97% and 92% full-length product with the NaM or TPT3 templates, respectively (FIG. 3, Table 1).
  • Table l Raw data for RNA concentration dependency of SuperScript III RT reaction full-length cDNA product ratio using RNA containing NaM or TPT3 .
  • An assay was developed to measure UBP retention quantitatively after sequential in vitro transcription (IVT) with T7 RNA polymerase and reverse transcription (RT) with the commercially available reverse transcriptases: Sup er Seri pt III, SuperScript IV and AMV reverse transcriptase.
  • IVT in vitro transcription
  • RT reverse transcription
  • the assay also analyzed the unnatural nucleotide content of the anti-sense DNA template (R(asDNA) (FIG. 4).
  • a 1.06
  • all sequences with either NaM or TPT3 produced full-length cDNA as the major product with combined T-RT retentions of 90% to 100% (FIG. 5 A, FIG. 6).
  • the unnatural base pair is transcribed (and reverse transcribed) in vitro with reasonable fidelity.
  • the HEK293T cells were provided with the AzK and transfected with mRNA and tRNA containing unnatural codons and anticodons, respectively, as well as a DNA plasmid encoding the chimeric PylRS which charges the mazei tRNA with AzK.
  • 80% of the DNA template used to prepare the mRNA contained the unnatural nucleotide and 70% of the protein expressed in vivo contained AzK.
  • the T-RT retention assay developed in Example 3 was used to characterize RNA isolated from the /./ coli SSO.
  • ML2 cells were transformed with the pSyn plasmid encoding the sfGFP gene containing 151 st codons AXC, GXC, or GXT and the M. mazei tRNA gene containing the corresponding anticodons GYT, GYC, or AYC, respectively.
  • the SSO was previously shown to produce unnatural protein with high fidelity (Fischer, E. C., etal., Nat. Chem. Biol.
  • T-RT fidelity assay was further used to explore the explore the dependence of transcription fidelity on unnatural ribonucleotide triphosphate concentration.
  • SSO harboring sfGFP(GXT) and M. mazei tRNA( AYC) was grown as above except that varying amounts of either NaMTP or TPT3TP were provided.
  • concentration of TPT3TP was held constant at 250 mM, and the concentration of NaMTP was decreased, retention of NaM in the mRNA remained high until the concentration dropped to less than 50 ⁇ M (FIGS. 8 A-B, Table 3).
  • RNA aptamers targeting a protein of interest libraries of RNA are first generated from DNAby IVT, subjected to selection to enrich the library in desired RNAs, converted by RT back into DNA for PCR amplification, and then analyzed or converted back into RNA by IVT and subjected to additional rounds of selection.
  • DNA containing the unnatural nucleotides must be efficiently reverse transcribed into RNA comprising the unnatural nucleotides.
  • a series of related DNA oligonucleotides with an unnatural nucleotide are converted into RNA with the corresponding unnatural nucleotide, which are then subjected to selection for inhibitory potency.
  • the oligonucleotides may be about 100 bases in length.
  • a region of about 40 nucleotides in an initial DNA oligonucleotide is randomized, and a single dNaMis incorporated at a plurality (e.g., 3) of different positions of the region, flanked by barcode sequences (to identify the unnatural nucleotide position) and primer binding sequences.
  • a plurality (e.g., 3) of related DNA libraries are thus generated.
  • An equimolar mixture of the plurality of randomized oligonucleotide libraries is PCR amplified in reactions that include dTPT3TP and dNaMTP.
  • the primer that primes synthesis of the dTPT3 nucleotide includes a biotin tag attached to its 5 ’ end via a disulfide, or other cleavable moiety, which are commercially available and commonly used.
  • the dsDNA is purified by binding to streptavidin coated magnetic beads, subjecting the beads to buffer washing steps, and then washing with 0.1 mMNaOHto elute the dNaM-containing ssDNA library.
  • the dTPT3 -containing ssDNA library can be released from the beads by reductive cleavage using 30 mM Tris(2-carboxyethyl)phosphine (TCEP) (or any other suitable reagent). Either ssDNA library can then be used as template for a T7 RNA polymerase-mediated IVT reaction supplemented with the appropriate unnatural ribotriphosphate (TPT3TP orNaMTP). DNA is degraded nucleolytically and the library is purified (e.g., with a spin column such as the Zymo ssDNA/RNA purification kit).
  • TCEP Tris(2-carboxyethyl)phosphine
  • the library is folded.
  • the resulting folded library is then subjected to selection for binding to the protein of interest.
  • the library is incubated with the target protein of interest, for example immobilized on high-protein adsorption ELISA plates, washed, and then eluted by washing three times with formamide.
  • Selection pressure for binding to the protein of interest is increased through various methods, including by gradually in sub sequent rounds of selection raising the concentration of salt in the washing buffer or adding yeast tRNA as a binding competitor in the binding buffer. After each round of selection, the RNAs that bind to the protein of interest are isolated, and the RNA oligonucleotides are eluted.
  • RNA oligonucleotides are reverse transcribed into cDNA accordingto methods described herein.
  • the cDNA is PCR amplified with dTPT3TP and dNaMTP and with the same biotinylated primer, and subjected to additional rounds of selection as desired, thereby providing an enriched set of aptamer.
  • the enriched individual RNA aptamers are reverse transcribed into cDNA, PCR amplified, and sequenced (e.g., wherein the unnatural nucleotide is replaced with a natural nucleotide for sequencing, and the barcode sequences are relied upon for identification of the unnatural nucleotide position). Sequence homology among the enriched RNA oligonucleotides is studied, and a subset of sequences are selected for further characterization. Selected RNA aptamers are then synthesized and folded. Each aptamer is then individually analyzed for its ability to bind the target protein (or inhibit its activity if the target protein is an enzyme).
  • RNA oligonucleotides can be reverse transcribed into cDNA, and its sequence randomized further via error-prone PCR to generate additional libraries for further rounds of selection.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2021/056334 2020-10-23 2021-10-22 Reverse transcription of polynucleotides comprising unnatural nucleotides Ceased WO2022087475A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA3196205A CA3196205A1 (en) 2020-10-23 2021-10-22 Reverse transcription of polynucleotides comprising unnatural nucleotides
AU2021364920A AU2021364920A1 (en) 2020-10-23 2021-10-22 Reverse transcription of polynucleotides comprising unnatural nucleotides
JP2023524597A JP2023547615A (ja) 2020-10-23 2021-10-22 非天然ヌクレオチドを含むポリヌクレオチドの逆転写
KR1020237016545A KR20230088898A (ko) 2020-10-23 2021-10-22 비천연 뉴클레오티드를 포함하는 폴리뉴클레오티드의 역전사
IL302243A IL302243A (en) 2020-10-23 2021-10-22 Reverse transcription of polynucleotides comprising unnatural nucleotides
MX2023004690A MX2023004690A (es) 2020-10-23 2021-10-22 Transcripcion inversa de polinucleotidos que comprenden nucleotidos no naturales.
CN202180079118.6A CN116761885A (zh) 2020-10-23 2021-10-22 包含非天然核苷酸的多核苷酸的逆转录
EP21884025.4A EP4232570A4 (en) 2020-10-23 2021-10-22 REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES WITH UNNATURAL NUCLEOTIDES
US18/304,993 US20230392140A1 (en) 2020-10-23 2023-04-21 Reverse transcription of polynucleotides comprising unnatural nucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063104785P 2020-10-23 2020-10-23
US63/104,785 2020-10-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/304,993 Continuation US20230392140A1 (en) 2020-10-23 2023-04-21 Reverse transcription of polynucleotides comprising unnatural nucleotides

Publications (1)

Publication Number Publication Date
WO2022087475A1 true WO2022087475A1 (en) 2022-04-28

Family

ID=81289498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/056334 Ceased WO2022087475A1 (en) 2020-10-23 2021-10-22 Reverse transcription of polynucleotides comprising unnatural nucleotides

Country Status (11)

Country Link
US (1) US20230392140A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232570A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023547615A (cg-RX-API-DMAC7.html)
KR (1) KR20230088898A (cg-RX-API-DMAC7.html)
CN (1) CN116761885A (cg-RX-API-DMAC7.html)
AU (1) AU2021364920A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196205A1 (cg-RX-API-DMAC7.html)
IL (1) IL302243A (cg-RX-API-DMAC7.html)
MX (1) MX2023004690A (cg-RX-API-DMAC7.html)
TW (1) TW202227100A (cg-RX-API-DMAC7.html)
WO (1) WO2022087475A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634451B2 (en) 2013-08-08 2023-04-25 The Scripps Research Institute Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
US11761007B2 (en) 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
US11834479B2 (en) 2016-06-24 2023-12-05 The Scripps Research Institute Nucleoside triphosphate transporter and uses thereof
US11834689B2 (en) 2017-07-11 2023-12-05 The Scripps Research Institute Incorporation of unnatural nucleotides and methods thereof
US12173291B2 (en) 2017-12-29 2024-12-24 The Scripps Research Institute Unnatural base pair compositions and methods of use
US12655436B2 (en) 2014-04-09 2026-06-16 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters

Citations (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4667025A (en) 1982-08-09 1987-05-19 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4835263A (en) 1983-01-27 1989-05-30 Centre National De La Recherche Scientifique Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis and their use
US4845205A (en) 1985-01-08 1989-07-04 Institut Pasteur 2,N6 -disubstituted and 2,N6 -trisubstituted adenosine-3'-phosphoramidites
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US4876335A (en) 1986-06-30 1989-10-24 Wakunaga Seiyaku Kabushiki Kaisha Poly-labelled oligonucleotide derivative
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US4981957A (en) 1984-07-19 1991-01-01 Centre National De La Recherche Scientifique Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini
US5015733A (en) 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5112963A (en) 1987-11-12 1992-05-12 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Modified oligonucleotides
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
US5319080A (en) 1991-10-17 1994-06-07 Ciba-Geigy Corporation Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
WO1994014226A1 (en) 1992-12-14 1994-06-23 Honeywell Inc. Motor system with individually controlled redundant windings
EP0614907A1 (en) 1993-03-06 1994-09-14 Ciba-Geigy Ag Dinucleotide and oligonucleotide analogues
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
EP0629633A2 (en) 1993-06-05 1994-12-21 Ciba-Geigy Ag Dinucleotide analogues, intermediates therefor and oligonucleotides derived therefrom
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5405939A (en) 1987-10-22 1995-04-11 Temple University Of The Commonwealth System Of Higher Education 2',5'-phosphorothioate oligoadenylates and their covalent conjugates with polylysine
US5414077A (en) 1990-02-20 1995-05-09 Gilead Sciences Non-nucleoside linkers for convenient attachment of labels to oligonucleotides using standard synthetic methods
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5446137A (en) 1993-12-09 1995-08-29 Syntex (U.S.A.) Inc. Oligonucleotides containing 4'-substituted nucleotides
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5455233A (en) 1989-11-30 1995-10-03 University Of North Carolina Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5466786A (en) 1989-10-24 1995-11-14 Gilead Sciences 2'modified nucleoside and nucleotide compounds
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5510475A (en) 1990-11-08 1996-04-23 Hybridon, Inc. Oligonucleotide multiple reporter precursors
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5514785A (en) 1990-05-11 1996-05-07 Becton Dickinson And Company Solid supports for nucleic acid hybridization assays
US5519126A (en) 1988-03-25 1996-05-21 University Of Virginia Alumni Patents Foundation Oligonucleotide N-alkylphosphoramidates
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5545730A (en) 1984-10-16 1996-08-13 Chiron Corporation Multifunctional nucleic acid monomer
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5552540A (en) 1987-06-24 1996-09-03 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5567811A (en) 1990-05-03 1996-10-22 Amersham International Plc Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5567810A (en) 1990-08-03 1996-10-22 Sterling Drug, Inc. Nuclease resistant compounds
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5576427A (en) 1993-03-30 1996-11-19 Sterling Winthrop, Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5587371A (en) 1992-01-21 1996-12-24 Pharmacyclics, Inc. Texaphyrin-oligonucleotide conjugates
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5610300A (en) 1992-07-01 1997-03-11 Ciba-Geigy Corporation Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5639873A (en) 1992-02-05 1997-06-17 Centre National De La Recherche Scientifique (Cnrs) Oligothionucleotides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5645985A (en) 1991-11-26 1997-07-08 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5658873A (en) 1993-04-10 1997-08-19 Degussa Aktiengesellschaft Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions containing them
US5663312A (en) 1993-03-31 1997-09-02 Sanofi Oligonucleotide dimers with amide linkages replacing phosphodiester linkages
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
WO1997035869A1 (en) 1996-03-23 1997-10-02 Novartis Ag Dinucleotide and oligonucleotide analogues
US5677439A (en) 1990-08-03 1997-10-14 Sanofi Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleotide analogues
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5750692A (en) 1990-01-11 1998-05-12 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5830653A (en) 1991-11-26 1998-11-03 Gilead Sciences, Inc. Methods of using oligomers containing modified pyrimidines
WO1999062923A2 (en) 1998-06-05 1999-12-09 Dynavax Technologies Corporation Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6268490B1 (en) 1997-03-07 2001-07-31 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6670461B1 (en) 1997-09-12 2003-12-30 Exiqon A/S Oligonucleotide analogues
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US20040171570A1 (en) 2002-11-05 2004-09-02 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005021570A1 (ja) 2003-08-28 2005-03-10 Gene Design, Inc. N−0結合性架橋構造型新規人工核酸
US20050130923A1 (en) 2003-09-18 2005-06-16 Balkrishen Bhat 4'-thionucleosides and oligomeric compounds
US20050187180A1 (en) * 1996-10-28 2005-08-25 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
US20060074035A1 (en) 2002-04-17 2006-04-06 Zhi Hong Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US20080039618A1 (en) 2002-11-05 2008-02-14 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
US20110098461A1 (en) * 2000-08-02 2011-04-28 University Of Southern California Novel RNA Interference Methods Using DNA-RNA Duplex Constructs
US9201020B2 (en) 2011-10-25 2015-12-01 Apogee Enterprises, Inc. Specimen viewing device
US20160069889A1 (en) * 2012-12-19 2016-03-10 Caris Science, Inc. Compositions and methods for aptamer screening
US9402993B2 (en) 2011-04-11 2016-08-02 Boston Scientific Neuromodulation Corporation Systems and methods for enhancing paddle lead placement
US20170029791A1 (en) * 2011-12-08 2017-02-02 Roche Molecular Systems, Inc. Dna polymerases with improved activity
US20170101675A1 (en) * 2014-05-19 2017-04-13 The Trustees Of Columbia University In The City Of New York Ion sensor dna and rna sequencing by synthesis using nucleotide reversible terminators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354225B1 (en) * 2004-08-28 2013-01-15 Steven Albert Benner Amplification of oligonucleotides containing non-standard nucleobases
EP3475295B1 (en) * 2016-06-24 2022-08-10 The Scripps Research Institute Novel nucleoside triphosphate transporter and uses thereof

Patent Citations (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4667025A (en) 1982-08-09 1987-05-19 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4789737A (en) 1982-08-09 1988-12-06 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives and production thereof
US4835263A (en) 1983-01-27 1989-05-30 Centre National De La Recherche Scientifique Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis and their use
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US5541313A (en) 1983-02-22 1996-07-30 Molecular Biosystems, Inc. Single-stranded labelled oligonucleotides of preselected sequence
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5015733A (en) 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4981957A (en) 1984-07-19 1991-01-01 Centre National De La Recherche Scientifique Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini
US5578717A (en) 1984-10-16 1996-11-26 Chiron Corporation Nucleotides for introducing selectably cleavable and/or abasic sites into oligonucleotides
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5552538A (en) 1984-10-16 1996-09-03 Chiron Corporation Oligonucleotides with cleavable sites
US5545730A (en) 1984-10-16 1996-08-13 Chiron Corporation Multifunctional nucleic acid monomer
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4845205A (en) 1985-01-08 1989-07-04 Institut Pasteur 2,N6 -disubstituted and 2,N6 -trisubstituted adenosine-3'-phosphoramidites
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
US4876335A (en) 1986-06-30 1989-10-24 Wakunaga Seiyaku Kabushiki Kaisha Poly-labelled oligonucleotide derivative
US5286717A (en) 1987-03-25 1994-02-15 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5552540A (en) 1987-06-24 1996-09-03 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5405939A (en) 1987-10-22 1995-04-11 Temple University Of The Commonwealth System Of Higher Education 2',5'-phosphorothioate oligoadenylates and their covalent conjugates with polylysine
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
US5112963A (en) 1987-11-12 1992-05-12 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Modified oligonucleotides
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
US5519126A (en) 1988-03-25 1996-05-21 University Of Virginia Alumni Patents Foundation Oligonucleotide N-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5453496A (en) 1988-05-26 1995-09-26 University Patents, Inc. Polynucleotide phosphorodithioate
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5416203A (en) 1989-06-06 1995-05-16 Northwestern University Steroid modified oligonucleotides
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5466786B1 (en) 1989-10-24 1998-04-07 Gilead Sciences 2' Modified nucleoside and nucleotide compounds
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5466786A (en) 1989-10-24 1995-11-14 Gilead Sciences 2'modified nucleoside and nucleotide compounds
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5455233A (en) 1989-11-30 1995-10-03 University Of North Carolina Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5587469A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides containing N-2 substituted purines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5750692A (en) 1990-01-11 1998-05-12 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5414077A (en) 1990-02-20 1995-05-09 Gilead Sciences Non-nucleoside linkers for convenient attachment of labels to oligonucleotides using standard synthetic methods
US5563253A (en) 1990-03-08 1996-10-08 Worcester Foundation For Biomedical Research Linear aminoalkylphosphoramidate oligonucleotide derivatives
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5536821A (en) 1990-03-08 1996-07-16 Worcester Foundation For Biomedical Research Aminoalkylphosphorothioamidate oligonucleotide deratives
US5541306A (en) 1990-03-08 1996-07-30 Worcester Foundation For Biomedical Research Aminoalkylphosphotriester oligonucleotide derivatives
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5567811A (en) 1990-05-03 1996-10-22 Amersham International Plc Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5514785A (en) 1990-05-11 1996-05-07 Becton Dickinson And Company Solid supports for nucleic acid hybridization assays
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5677439A (en) 1990-08-03 1997-10-14 Sanofi Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleotide analogues
US5567810A (en) 1990-08-03 1996-10-22 Sterling Drug, Inc. Nuclease resistant compounds
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5510475A (en) 1990-11-08 1996-04-23 Hybridon, Inc. Oligonucleotide multiple reporter precursors
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5319080A (en) 1991-10-17 1994-06-07 Ciba-Geigy Corporation Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates
US5393878A (en) 1991-10-17 1995-02-28 Ciba-Geigy Corporation Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5830653A (en) 1991-11-26 1998-11-03 Gilead Sciences, Inc. Methods of using oligomers containing modified pyrimidines
US5645985A (en) 1991-11-26 1997-07-08 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5587371A (en) 1992-01-21 1996-12-24 Pharmacyclics, Inc. Texaphyrin-oligonucleotide conjugates
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5639873A (en) 1992-02-05 1997-06-17 Centre National De La Recherche Scientifique (Cnrs) Oligothionucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5700920A (en) 1992-07-01 1997-12-23 Novartis Corporation Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5610300A (en) 1992-07-01 1997-03-11 Ciba-Geigy Corporation Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
WO1994014226A1 (en) 1992-12-14 1994-06-23 Honeywell Inc. Motor system with individually controlled redundant windings
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5466677A (en) 1993-03-06 1995-11-14 Ciba-Geigy Corporation Dinucleoside phosphinates and their pharmaceutical compositions
EP0614907A1 (en) 1993-03-06 1994-09-14 Ciba-Geigy Ag Dinucleotide and oligonucleotide analogues
US5576427A (en) 1993-03-30 1996-11-19 Sterling Winthrop, Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5663312A (en) 1993-03-31 1997-09-02 Sanofi Oligonucleotide dimers with amide linkages replacing phosphodiester linkages
US5658873A (en) 1993-04-10 1997-08-19 Degussa Aktiengesellschaft Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions containing them
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
EP0629633A2 (en) 1993-06-05 1994-12-21 Ciba-Geigy Ag Dinucleotide analogues, intermediates therefor and oligonucleotides derived therefrom
US5763588A (en) 1993-09-17 1998-06-09 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US6005096A (en) 1993-09-17 1999-12-21 Gilead Sciences, Inc. Pyrimidine derivatives
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137A (en) 1993-12-09 1995-08-29 Syntex (U.S.A.) Inc. Oligonucleotides containing 4'-substituted nucleotides
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5599928A (en) 1994-02-15 1997-02-04 Pharmacyclics, Inc. Texaphyrin compounds having improved functionalization
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5591584A (en) 1994-08-25 1997-01-07 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
WO1997035869A1 (en) 1996-03-23 1997-10-02 Novartis Ag Dinucleotide and oligonucleotide analogues
US20050187180A1 (en) * 1996-10-28 2005-08-25 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6268490B1 (en) 1997-03-07 2001-07-31 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6670461B1 (en) 1997-09-12 2003-12-30 Exiqon A/S Oligonucleotide analogues
US7034133B2 (en) 1997-09-12 2006-04-25 Exiqon A/S Oligonucleotide analogues
WO1999062923A2 (en) 1998-06-05 1999-12-09 Dynavax Technologies Corporation Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US20110098461A1 (en) * 2000-08-02 2011-04-28 University Of Southern California Novel RNA Interference Methods Using DNA-RNA Duplex Constructs
US20060074035A1 (en) 2002-04-17 2006-04-06 Zhi Hong Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections
US20040171570A1 (en) 2002-11-05 2004-09-02 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20080039618A1 (en) 2002-11-05 2008-02-14 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005021570A1 (ja) 2003-08-28 2005-03-10 Gene Design, Inc. N−0結合性架橋構造型新規人工核酸
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
US20050130923A1 (en) 2003-09-18 2005-06-16 Balkrishen Bhat 4'-thionucleosides and oligomeric compounds
US7399845B2 (en) 2006-01-27 2008-07-15 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US20070287831A1 (en) 2006-05-11 2007-12-13 Isis Pharmaceuticals, Inc 5'-modified bicyclic nucleic acid analogs
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
US9402993B2 (en) 2011-04-11 2016-08-02 Boston Scientific Neuromodulation Corporation Systems and methods for enhancing paddle lead placement
US9201020B2 (en) 2011-10-25 2015-12-01 Apogee Enterprises, Inc. Specimen viewing device
US20170029791A1 (en) * 2011-12-08 2017-02-02 Roche Molecular Systems, Inc. Dna polymerases with improved activity
US20160069889A1 (en) * 2012-12-19 2016-03-10 Caris Science, Inc. Compositions and methods for aptamer screening
US20170101675A1 (en) * 2014-05-19 2017-04-13 The Trustees Of Columbia University In The City Of New York Ion sensor dna and rna sequencing by synthesis using nucleotide reversible terminators

Non-Patent Citations (79)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. U07128
AKBERGENOV ET AL., NUCLEIC ACIDS RESEARCH, vol. 32, 2004, pages 239 - 247
ALEXEI A. KOSHKINSANJAY K. SINGHPOUL NIELSENVIVEK K. RAJWANSHIRAVINDRA KUMARMICHAEL MELDGAARDCARL ERIK OLSENJESPER WENGEL: "LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition", TETRAHEDRON, vol. 54, no. 14, 1998, pages 3607 - 30
BOHRINGER ET AL., TET. LETT, vol. 34, 1993, pages 2723 - 2726
BRAASCH ET AL., CHEM. BIOL, vol. 8, 2001, pages 1 - 7
CHATTOPADHYAYA ET AL., J. ORG. CHEM., vol. 209, no. 74, 1998, pages 10035 - 10039
CHATURVEDI ET AL., NUCLEIC ACIDS RES., vol. 24, 1996, pages 2966 - 2973
CHEN ET AL., PHOSPHORUS, SULFUR AND SILICON, vol. 777, 2002, pages 1783 - 1786
COLLINGWOOD ET AL., SYNLETT, vol. 7, 1995, pages 703 - 705
CROOKE ET AL., J. PHARMACOL. EXP. THER., vol. 277, 1996, pages 923 - 937
EGGERT ET AL.: "Towards Reverse Transcription with an Expanded Genetic Alphabet", CHEMBIOCHEM, vol. 20, 2019, pages 1642 - 1645, XP093195222, DOI: 10.1002/cbic.201800808
EGHOLM MBUCHARDT OCHRISTENSEN LBEHRENS CFREIER SMDRIVER DABERG RHKIM SKNORDÉN BNIELSEN PE: "PNA Hybridizes to Complementary Oligonucleotides Obeying the Watson-Crick Hydrogen Bonding Rules", NATURE, vol. 365, no. 6446, 1993, pages 566 - 8, XP002030791, DOI: 10.1038/365566a0
ELAYADI ET AL., CURR. OPINION INVENS. DRUGS, vol. 2, 2001, pages 558 - 561
EPPACHER ET AL., HELVETICA CHIMICA ACTA, vol. 87, 2004, pages 3004 - 3020
FAIRHURST ET AL., SYNLETT, vol. 4, 2001, pages 467 - 472
FISCHER, E. C. ET AL., NAT. CHEM. BIOL., no. 16, 2020, pages 570 - 576
FISCHER, E. C. ET AL.: "New Codons for Efficient Production of Unnatural Proteins in a Semisynthetic Organism", NAT. CHEM. BIOL., vol. 16, 2020, pages 570 - 576, XP093195227, DOI: 10.1038/s41589-020-0507-z
GALLIE ET AL., NUCLEIC ACIDS RESEARCH, vol. 15, 1987, pages 3257 - 3273
GALLIE, NUCLEIC ACIDS RESEARCH, vol. 30, 2002, pages 3401 - 3411
GALLIER ET AL., EUR. J. ORG. CHEM., 2007, pages 925 - 933
GEZE ET AL., J. AM. CHEM. SOC, vol. 105, no. 26, 1983, pages 7638 - 7640
HAMPTON ET AL., J. AM. CHEM. SOC, vol. 95, no. 13, 1973, pages 4404 - 4414
HAMPTON ET AL., J. MED. CHEM., vol. 19, no. 8, 1976, pages 1371 - 1377
HAO, B. ET AL., SCIENCE, vol. 296, 2002, pages 1462 - 1466
HUTTER ET AL., HELVETICA CHIMICA ACTA, vol. 85, 2002, pages 2777 - 2806
JAGER ET AL., BIOCHEM., vol. 27, 1988, pages 7247 - 7246
JUNG ET AL., BIOORG. MED. CHEM., vol. 8, 2000, pages 2501 - 2509
KABANOV ET AL., FEBS LETT., vol. 259, 1990, pages 327 - 330
KANDIMALLA ET AL., BIOORG. MED. CHEM., vol. 9, 2001, pages 807 - 813
KAPPLER ET AL., J. MED. CHEM., vol. 25, 1982, pages 1179 - 1184
KAPPLER ET AL., J. MED. CHEM., vol. 29, 1986, pages 1030 - 1038
KAUR, HARORA, AWENGEL, JMAITI, S: "Thermodynamic, Counterion, and Hydration Effects for the Incorporation of Locked Nucleic Acid Nucleotides into DNA Duplexes", BIOCHEMISTRY, vol. 45, no. 23, 2006, pages 7347 - 55
KOSHKIN ET AL., TETRAHEDRON, vol. 54, 1998, pages 3607 - 3630
KRYUKOV, G. V. ET AL., SCIENCE, vol. 300, 2003, pages 1439 - 1443
KUMAR ET AL., BIOORG. MED. CHEM. LETT, vol. 8, 1998, pages 2219 - 2222
LEAL ET AL.: "Transcription, Reverse Transcription, and Analysis of RNA Containing Artificial Genetic Components", ACS SYNTHETIC BIOLOGY, vol. 4, no. 4, 2014, pages 407 - 413, XP093195221, DOI: 10.1021/sb500268n
LETSINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6553 - 6556
MALYSHEV, D. A. ET AL.: "A Semi-Synthetic Organism with an Expanded Genetic Alphabet.", NATURE, vol. 509, 2014, pages 385 - 388, XP055391821, DOI: 10.1038/nature13314
MANOHARAN ET AL., ANN. KY. ACAD. SCI, vol. 660, 1992, pages 306 - 309
MANOHARAN ET AL., BIOORG. MED. CHEM. LET, vol. 3, 1993, pages 2765 - 2770
MANOHARAN ET AL., BIOORG. MED. CHEM. LET., vol. 4, 1994, pages 1053 - 1060
MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, vol. 14, 1995, pages 969 - 973
MANOHARAN ET AL., TETRAHEDRON LETT., vol. 36, 1995, pages 3651 - 3654
MESMAEKER ET AL., SYNLETT, 1997, pages 1287 - 1290
MICKLEFIELD, CURR. MED. CHEM., vol. 8, 2001, pages 1157 - 1179
MICKLEFIELD, CURRENT MEDICINAL CHEMISTRY, vol. 8, 2001, pages 1157 - 1179
MIGNONE ET AL., GENOME BIOLOGY, vol. 3, no. 3
MIGNONE ET AL., NUCLEIC ACIDS RESEARCH, vol. 33, 2005, pages D141 - D146
MIKHAILOV ET AL., NUCLEOSIDES & NUCLEOTIDES, vol. 10, no. 1-3, 1991, pages 339 - 343
MILLER ET AL., JACS, vol. 93, 1971, pages 6657 - 6665
MISHRA ET AL., BIOCHEM. BIOPHYS. ACTA, vol. 1264, 1995, pages 229 - 237
NAWROT ET AL., OLIGONUCLEOTIDES, vol. 16, no. 1, 2006, pages 68 - 82
NELSON ET AL., JOC, vol. 62, 1997, pages 7278 - 7287
NIELSEN ET AL., SCIENCE, vol. 254, 1991, pages 1497 - 1500
NIELSEN PEEGHOLM MBERG RHBUCHARDT O: "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide", SCIENCE, vol. 254, no. 5037, December 1991 (1991-12-01), pages 1497 - 500, XP002912953, DOI: 10.1126/science.1962210
OBERHAUSER ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 533 - 538
ORAM ET AL., CURR. OPINION MOL. THER., vol. 3, 2001, pages 239 - 243
OWCZARZY R.; YOU Y., GROTH C.L., TATAUROV A.V.: "Stability and mismatch discrimination of locked nucleic acid-DNA duplexes.", BIOCHEM., vol. 50, no. 43, 2011, pages 9352 - 9367, XP055012733, DOI: 10.1021/bi200904e
PAULOUS ET AL., NUCLEIC ACIDS RESEARCH, vol. 31, 2003, pages 722 - 733
SAHA ET AL., J. ORG CHEM., vol. 60, 1995, pages 788 - 789
SAISON-BEHMOARAS ET AL., EM5OJ, vol. 10, 1991, pages 1111 - 1118
SATOSHI OBIKADAISHU NANBUYOSHIYUKI HARIKEN-ICHIRO MORIOYASUKO INTOSHIMASA ISHIDATAKESHI IMANISHI: "Synthesis of 2'-0,4'-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3'-endo sugar puckering", TETRAHEDRON LETT., vol. 38, no. 50, 1997, pages 8735 - 8
See also references of EP4232570A4
SHEA ET AL., NUCL. ACIDS RES., vol. 18, 1990, pages 3777 - 3783
SINGH ET AL., CHEM. COMMUN., vol. 4, 1998, pages 455 - 456
SRIVASTAVA ET AL., J. AM. CHEM. SOC., vol. 129, no. 26, 2007, pages 8362 - 8379
SVINARCHUK ET AL., BIOCHIMIE, vol. 75, 1993, pages 49 - 54
VRUDHULA ET AL., J. MED. CHEM., vol. 30, 1987, pages 888 - 894
WAHLESTEDT ET AL., PROC. NATL. ACAD. SCI. U. S. A., vol. 97, 2000, pages 5633 - 5638
WANG ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, 1999, pages 885 - 890
WANG ET AL., NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, vol. 23, no. 1,2, 2004, pages 317 - 337
WANG, L. ET AL., ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 35, 2006, pages 225 - 249
WU ET AL., BIOCONJUGATE CHEM., vol. 10, 1999, pages 921 - 924
WU ET AL., HELVETICA CHIMICA ACTA, vol. 83, 2000, pages 1127 - 1143
XIAO, H. ET AL., COLD SPRING HARB. PERSPECT. BIOL., vol. 8, 2016
YUAN, J. ET AL., FEBS LETT., vol. 584, 2010, pages 342 - 349
ZHANG, Y. ET AL., NATURE, vol. 551, 2017, pages 644 - 647
ZHOU ET AL.: "Progress toward Eukaryotic Semisynthetic Organisms: Translation of Unnatural Codons.", J. AM. CHEM. SOC., vol. 141, no. 13803-65-1, 2019, pages 20166 - 20170, XP093054220, DOI: 10.1021/jacs.9b09080
ZON: "Protocols for Oligonucleotides and Analogs, Synthesis and Properties", 1993, HUMANA PRESS, article "Oligonucleoside Phosphorothioates", pages: 165 - 190

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634451B2 (en) 2013-08-08 2023-04-25 The Scripps Research Institute Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
US12281137B2 (en) 2013-08-08 2025-04-22 The Scripps Research Institute Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
US12655436B2 (en) 2014-04-09 2026-06-16 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
US11761007B2 (en) 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
US11834479B2 (en) 2016-06-24 2023-12-05 The Scripps Research Institute Nucleoside triphosphate transporter and uses thereof
US11834689B2 (en) 2017-07-11 2023-12-05 The Scripps Research Institute Incorporation of unnatural nucleotides and methods thereof
US12319944B2 (en) 2017-07-11 2025-06-03 The Scripps Research Institute Incorporation of unnatural nucleotides and methods thereof
US12173291B2 (en) 2017-12-29 2024-12-24 The Scripps Research Institute Unnatural base pair compositions and methods of use

Also Published As

Publication number Publication date
IL302243A (en) 2023-06-01
US20230392140A1 (en) 2023-12-07
TW202227100A (zh) 2022-07-16
AU2021364920A9 (en) 2024-09-12
AU2021364920A1 (en) 2023-06-22
MX2023004690A (es) 2023-05-09
CA3196205A1 (en) 2022-04-28
JP2023547615A (ja) 2023-11-13
CN116761885A (zh) 2023-09-15
KR20230088898A (ko) 2023-06-20
EP4232570A1 (en) 2023-08-30
EP4232570A4 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
US20230392140A1 (en) Reverse transcription of polynucleotides comprising unnatural nucleotides
JP2023175678A (ja) 非天然ヌクレオチドの組み込み及びその方法
US11879145B2 (en) Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
EP3475295B1 (en) Novel nucleoside triphosphate transporter and uses thereof
CA3153855A1 (en) Compositions and methods for in vivo synthesis of unnatural polypeptides
CA3151762A1 (en) Eukaryotic semi-synthetic organisms

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21884025

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3196205

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023524597

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202317030845

Country of ref document: IN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023007197

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20237016545

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202180079118.6

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2021884025

Country of ref document: EP

Effective date: 20230523

ENP Entry into the national phase

Ref document number: 112023007197

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230418

ENP Entry into the national phase

Ref document number: 2021364920

Country of ref document: AU

Date of ref document: 20211022

Kind code of ref document: A